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Abstract

ANALYSIS AND FINGERPRINTING OF GLYCOSAMINOGLYCANS
By Joseph Timothy King, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Umesh R. Desai
Professor, Department of Medicinal Chemistry

Heparin is a complex mixture of sulfated polysaccharides derived from animals and
one of the oldest drugs in use. While an efficacious anticoagulant, heparin is beset by
side effects and pharmacokinetic difficulties. Low molecular weight heparins (LMWH)
are made by depolymerizing unfractionated heparin (UFH) and have made
improvements in these areas. However, they still retain a phenomenally high level of
complexity due to their polydispersity and the introduction of non-native structural
features. This makes the structural characterization LMWHs a daunting task.
This work details the development of a novel capillary electrophoretic (CE) method
for fingerprinting LMWHs. Since their complexity normally results in a nearly featureless
electropherogram, polyalkylamines were used as a resolving agents to yield highly
resolved and reproducible fingerprints characteristic of the LMWH being investigated.

xiv

Linear polyamines of resolved LMWH in a manner dependent on chain length and
charge density, while cyclic polyamines were incapable of resolution. Longer length
glycosaminoglycans such as UFH and chondroitin sulfate were not successfully
fingerprinted as they lacked run to run consistency. Further investigation into the mode
of polyamine binding showed that they bound to LMWH via a two site binding model,
indicating the presence of specific sites on LMWH that tightly bind polyamines. Upon
the saturation of these sites, the polyamines continue to interact via general
electrostatic binding. Pentaethylenehexamine was also able to separate the known
contaminant oversulfated chondroitin sulfate from UFH.
In July of 2010, the US food and drug administration approved a generic for the
widely used LMWH enoxaparin, a questionable move due to the difficulties of proving
the equivalence of such a complex mixture. A comparison of the brand and generic
batches of enoxaparin using the fingerprinting method revealed striking similarities,
bolstering the generic’s claim of equivalency and providing a protocol for the evaluation
of other biosimilar LMWHs.
This is the first work utilizing CE in developing high resolution fingerprints of LMWH.
It presents a noteworthy method for quality assessment of LMWH and provides the
basis for designing other small molecule probes for the analysis of complex
glycosaminoglycans.

xv

Introduction
1.1 The Structure, Source, and Pharmacological Properties of Heparin
Heparin is a heterogeneous, polydisperse, highly sulfated natural polysaccharide
that is widespread among species ranging from invertebrates, such as shrimp and
clams, to mammals, such as cows and humans [1-2]. Part of the larger family of
carbohydrates, known as glycosaminoglycans (GAGs), it is the oldest anticoagulant in
use and one of the longest serving pharmaceuticals [3]. Along with its closely related
cousin heparan sulfate (HS), it has been shown to interact with a myriad of proteins
such as antithrombin, granulocyte-colony stimulating factor, fibroblast growth factors,
chemokines such as interleukins, cellular adhesion proteins such as selectins and
fibronectin, pathogen proteins from herpes-simplex and human immunodeficiency
viruses, and many others [4-6]. The structural diversity of heparin and HS makes them
among the most difficult substances to analyze, but also gives them a rich biological
profile as evidenced by the numerous review articles detailing heparin/HS interactions
with proteins that have been published to date [2,4,6,7]. These promise much in the
area of drug discovery [7].
The biosynthesis of these polymers differs enormously from that of proteins in
that there is no template that codes for them. Instead, the synthesis of heparin, HS, and
related sugars is carried out by a host of enzymes that yield a complicated mixture of
molecules. The synthetic process begins with the building of a specific tetrasaccharide
sequence on a serine residue of a core protein. In the crucial step that follows, an
1

acetylated glucosamine (GlcNAc) is added to the tetrasaccharide, ensuring that the
resulting molecule will be heparin or HS rather than another GAG. The chain is
extended by adding glucuronic acid (GlcA) and GlcNAc in an alternating manner by the
work of GlcA/GlcN transferases, with GlcNAc(1→4)GlcA as the sequence. This is
followed by the N-deacetylation and subsequent N-sulfation of GlcNAc and then by the
epimerization of many glucuronic acids to iduronic acid by C-5 epimerase. Finally, 2-O,
3-O, and 6-O sulfotransferases extensively sulfate the sugar, making it one of the
strongest acids in nature. However, none of these enzymes modify the GAG backbone
to completion or in an equivalent manner. The resulting hodgepodge, appropriately
called unfractionated heparin (UFH), is a mixture of millions of structurally distinct
polysaccharides with an average molecular weight of ~15 kDa and an average chain
length of ~50 residues when harvested, yielding a astonishingly heterogeneous and
polydisperse mixture of molecules [6,8,9].
While heparin and HS are closely related, there are a number of key differences
between them. First, heparin chains are freed from the proteoglycan core by endo-β-Dglucuronidase after synthesis and are subsequently stored in the granules of mast cells
along with various positively charged proteases and histamine. In contrast, HS is found
on the surfaces of many cells and interacts with many proteins in the body [4,5]. HS is
also larger then heparin with a molecular weight range of 5-50 kDa and an average of
30 kDa, while heparin ranges from 5-40 kDa with an average of 12 kDa. Heparin is
extensively sulfated and most glucuronic acid residues are converted to iduronic acid
during synthesis (~90%,) while HS is less sulfated with a lesser degree of
epimierization. Thus, HS is more complex than heparin, having a higher degree of
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polydispersity and heterogeneity [5,9]. Related GAGs include chondroitin sulfate (CS),
dermatan sulfate (DS), and Keratan sulfate (KS), and hylauronic acid that differ from
heparin with relation to sugar conformation and composition, degree of sulfation, the
type of linkages between sugars, molecular weight, their location in the body, and their
functions. Representitive structures of several GAGs are pictured in figure 1 [6].
Heparin was discovered almost a century ago and began to see use as an
anticoagulant in the 1930’s [10]. Since then much has been discovered with respect to
the structure and mechanism responsible for this activity. Heparin inhibits blood
coagulation by binding to a highly positively charged site on antithrombin, a serpin,
specifically by a sequence known as the H5 pentasaccharide. While antithrombin is
always present in the blood, it is relatively inactive. The binding of H5 causes a
conformational change in the serpin that increases its ability to inhibit by several
hundred fold a number of coagulation proteases, but most notably factor Xa and factor
IIa (thrombin). This maintains normal hemostasis by preventing unwanted thrombosis
[11].
UFH’s longevity is a testimony to its therapeutic efficacy, but it is not without
problems. The drug exhibits irregular pharmacokinetics due to extensive protein binding
which makes routine monitoring of activated partial thromboplastin time (aPTT)
necessary if therapeutic anticoagulation is to be acheived and maintained. UFH and
may also cause osteoporosis with long term use [12]. The most alarming problem with
UFH is heparin-induced thrombocytopenia (HIT). HIT manifests itself by a precipitous
drop in platelets and is caused by antibodies that form against heparin-platelet factor 4
complexes. While it is an efficacious anticoagulant, these drawbacks make UFH an
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expensive and often risky drug to administer and largely limit its use to inpatient
settings.
1.2

The Structure and Pharmacological Properties of Low Molecular Weight

Heparin
Low molecular weight heparins (LMWH) were developed in the 1990’s by
depolymerizing UFH by various methods to yield a mixture of compounds between
2,000 and 9,000 daltons. While they share many chemical and therapeutic features
with UFH, LMWHs are distinct in a number of ways. They inhibit factor Xa to a greater
extent than thrombin because longer GAG chains are needed for this to occur [13,14].
LMWHs generally exhibit better pharmacokinetics due to less binding to plasma
proteins and platelets resulting in substantially fewer monitoring requirements. Less
binding to proteins, platelets, and osteoblasts decreases many of the undesirable side
effects, such as HIT and osteoporosis [12,13]. The risk of bleeding between LMWH and
UFH is similar as shown in a recent meta-analysis comparing UFH and enoxaparin in
patients receiving deep vein thrombosis (DVT) prophylaxis [15]. These features
represent a significant improvement over UFH and their prominence in the prevention
and treatment of venous thromboembolic disease and is even used in outpatient
settings [16,17].
One thing that has long been apparent concerning LMWHs is the diversity that
exists between varying brands and formulations. This diversity is determined by a
number of factors including: 1) the source of the crude heparin extract, 2) the quality
and rigor of the post extraction purification yielding clinical UFH, 3) the method by
which UFH is depolymerized to yield LMWH.

4

The latter is the most critical in

contributing to LMWH identity and in the introduction of novel structural features [2]. The
three brands of LMWH available in the US are tinzaparin (InnohepTM, Mr: 4500),
dalteparin (FragminTM, Mr:6000) and enoxaparin (LovenoxTM, Mr:4200). Tinzaparin is
manufactured via heparinase digestion to yield a smaller GAG chain with an
unsaturated uronate residue on the non-reducing end. Dalteparin is formed by treating
UFH with nitrous acid to yield LMWH molecules with a five-membered anhydromannitol
residue at the reducing end. Enoxaparin is manufactured under basic conditions
yielding a chain with an unsaturated uronate residue in a manner similar to tinzaparin
but with chains also containing a 1,6-anhydromannose on the reducing end (figure 2)
[2,18,19]. Because our ability to analyze these complex mixtures is limited, other
chemical features not found in UFH may also be present. This makes each brand on the
US and world market to be considered a distinct pharmacological entity that is not
interchangeable according to the FDA [13].
The uncertainty surrounding the structure of LMWHs has come to forefront in
recent years with the introduction of generic enoxaparin formulations. These are often
referred to as biosimilar LMWHs [20]. Several of these have appeared around the world
in the last decade, raising concerns over their chemical and therapeutic equivalence
[21]. Maddineni et al. compared two generic enoxaparin formulations from India and one
from

Brazil

with

LovenoxTM

using

a

battery

of

enzymatic,

chemical,

and

pharmacodynamic tests. While the activated partial thromboplastin time and
prothrombin time of all four were similar, the molecular weight varied from 3905 to 4339
daltons. LovenoxTM and the Indian brands were readily digested by heparinase, but the
Brazilian formulation was resistant to breakdown. Since these enzymes are highly
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dependent on the structural nuances of heparin, its inability to degrade it indicates a
manufacturing process that differs from that which yield the trade name product.
The immunogenic potential of these LMWHs is also of great concern especially
with regard to HIT. Gomes et al. compared LovenoxTM to CutenoxTM, a generic version
manufactured by Gland-Pharma in India in an open label study in Brazil. 110 healthy
volunteers were given 40 mg LovenoxTM and 110 were given 40 mg CutenoxTM daily for
10 days. Interestingly, there was a slight difference in antibody composition between the
groups at 10 days, with LovenoxTM having slightly more IgA with CutenoxTM leading to
more IgG. While very close to one another, the differences in antibody profiles may be
indicative of structural deviation caused by differing conditions of manufacture. It also
raises concerns over the possibility that these LMWHs interact differently with other
proteins in our body and lead to unforeseen side effects [22]. Since a generic LMWH
would not be required to go through the rigorous safety and efficacy trials as the
innovator, these may only be detected after it has seen wide usage. Yet, the cost of
developing a new drug provides a powerful incentive to move generics onto the market.
1.3 Current Issues in the Analysis of Heparin and Low Molecular Weight Heparin
In early 2008, an outbreak of hypersensitivity reactions to UFH manufactured by
Baxter Pharmaceuticals was reported in the US. Symptoms typically began a few
minutes from initiation of treatment and included hypotension, shortness of breath, and
edema. In the US, 81 U.S. fatalities were reported [23-25]. Analysis of these samples
revealed that they were contaminated with the oversulfated chondroitin sulfate (OSCS),
a product of the chemical oversulfation of CS [26]. This highly anionic, non-natural
GAG is able to mimic the anticoagulant effects of UFH and difficult to distinguish due to
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structural similarities due to its structural similarities (figure 1a). OSCS has been shown
to activate the plasma contact system beginning with factor XIIa. Factor XIIa is part of
the intrinsic coagulation pathway, but also converts prekallikrein to kallikrein when
activated. Kallikrein stimulates the production to bradykinin, a powerful vasodilator and
inflammatory promoter [23,27,28]. This tragedy has spawned the development of a wide
spectrum of analytical techniques for the detection of OSCS in heparin and has
prompted the FDA to revise its analytical protocol [29,30]. Given the complex nature of
UFH and the possibility of other contaminants, the need for rapid, high powered
protocols for heparin analysis is likely to continue.
On July 23, 2010 the food and drug administration (FDA) approved the first
generic version of enoxaparin for the US [31]. Manufactured by Momenta
Pharmaceuticals and marketed by Sandoz, it was approved by the FDA from an
abbreviated new drug application and did not undergo the extensive clinical trials of the
innovator product. Instead, the FDA examined physiochemical properties such as
molecular weight distribution, disaccharide composition, and the presence of the 1,6anhydromannose ring. In addition, “the FDA required not only biological and
biochemical assay data to demonstrate equivalent anticoagulant activity in vitro and in
vivo but also pharmacodynamic data from healthy human volunteers.” [32] While
achieving equivalence in these areas is notable, the fine structure of the drug remains a
mystery.
The staggering chemical complexity of heparin means that there are boundless
opportunities for biochemical studies. The 2008 contamination crisis along with the
development and approval of generic LMWHs has created a renewed sense of urgency
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in developing robust methods for the detection of contaminants and characterization of
the GAGs themselves. Nuclear magnetic resonance (NMR) methods, various
spectroscopic techniques, electrophoretic protocols, chromatographic methods, mass
spectrometry, and hyphenated techniques have appeared in increasing number. What
follows in sections 1.4-1.7 is a survey of the techniques used in the analysis of UFH and
LMWH with special attention to the fingerprinting of and purity of these drugs. Emphasis
is given to the ease of use of the assay, the time required to complete it, the cost of
equipment and materials, sensitivity, specificity, and overall usefulness of the methods.
1.4 Nuclear Magnetic Resonance of Heparins
Nuclear magnetic resonance (NMR) spectroscopy has been extensively used to
characterize heparins, Proton NMR (1H-NMR) was the first to be used to probe the
sugar backbone and the functional groups that decorate it in the 1960’s [33,34]. In
addition to 1H-NMR,

13

C-NMR and various 2-dimensional NMR methods have given us

substantial insight into GAG structure, meaning that NMR has been utilized in the study
of heparin far more than other spectroscopic techniques such as infrared or raman.
Disaccharides obtained after enzymatic digestion of heparin were first characterized by
1

H-NMR in 1971 by Perlin and Mackie [35]. Since then,

13

C-NMR and 2-D NMR

techniques including heteronuclear multiple quantum coherence (HMQC) [36],
correlation spectroscopy (COSY),

total correlation spectroscopy (TOCSY), nuclear

overhauser enhancement spectroscopy (NOESY), and

rotating frame nuclear

Overhauser enhancement spectroscopy (ROESY), have confirmed the structures of
these GAG building blocks as well as oligosaccharides [37-39]. These powerful
techniques have enabled elucidation of the structure of many heparin oligosaccharides,
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but efforts are hampered by the inherent randomness of sulfation and chain length. The
most extensive effort to characterize heparin oligosaccharides was performed by Pervin
et al. in 1995. This mammoth effort involved depolymerizing and fractionating massive
amounts of heparin to yield 50 grams of oligosaccharides of Mw<5,000. Fourteen
homogeneous GAGs were isolated ranging from disaccharide to tetradecasaccharide
and characterized using COSY. However, the internal uronic residues were
distinguishable only up to octasaccharide length sugars [35]. Given that heparin
contains chains far larger than tetradecasaccharide, even the most powerful NMR
techniques would be unable to establish the structures of full length heparin chains even
if purified to homogeneity.
Though NMR was previously shown to detect contaminants in heparin
preparations [40-42], the 2008 heparin contamination crisis has brought NMR into fresh
focus.

Rather than complete structural elucidation, efforts have been focused on

identifying glycosaminoglycan contaminants in UFH by observing subtle differences in
NMR spectra. Most analyses since 2008 have relied on the presence of a downfield
shift of the N-acetyl signal in 1H-NMR. This results due to the change in electronic
character of the local carbon as a result of the increase in negative charge. Guerrini et
al. was the first to identify the OSCS contaminant in 2008 using

1

H-NMR. The

contaminating OSCS was differentiated from UFH and the natural impurity DS by a
downfield shift of the N-acetyl signal from 2.04 to 2.16 ppm in the 1H-NMR spectrum.
DS showed a chemical shift of 2.08 [26]. This confirmed the work previously published
by Maryuna et al. in 1998 [43]. Since then, the results of more than one hundred
heparin batches have been tested [44,45,30]. Beyer et al. quantitatively determined the
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amount OSCS and DS present in 108 samples of UFH with OSCS having an LOD of
0.1% of a 25 mg sample of UFH [44]. The protocol has been applied to crude UFH and
to the active pharmaceutical ingredient (API) [46]. It should be noted that many other
peaks beside the N-acetyl signal are indicative of OSCS contamination, but their
proximity to other signals makes reliable distinction difficult especially at low OSCS
concentrations [44,45]. The robustness and low limit of detection of this method caused
the FDA and U.S. Pharmacopia (USP) to mandate the use of 1H-NMR in the testing of
individual UFH batches [29,30].
1

H-NMR has also been coupled to other powerful analytical and chemometric

techniques. In 2005, Korir et al. characterized a pair of dissacharides and a
tetrasaccharide with tandem capillary electrophoresis-NMR (CE-NMR) using capillary
isotachophoresis, a mechanism allowing for sampe . Though the large amount of
sample required for NMR makes CE-NMR largely impractical at this point, further
technological advances may allow them to regularly be used in tandem [47]. Limtiaco et
al. used weak anion exchange high performance liquid chromatography (HPLC)
coupled to 1H-NMR to study OSCS, UFH, CS, and DS. Run conditions were optimized
to allow for a nearly 8 minute baseline separation of OSCS and UFH using a 0.1-1 M
NaCl gradient. Using D2O based buffer, distinctive on flow 1H-NMR profiles of UFH and
OSCS could be acquired. Stopped flow NMR allowed the GAGs a much longer
residence in the flow cell and yielded a far more detailed spectra in which many peak
assignments were possible for UFH, CS A, DS, and OSCS with enough resolution and
sensitivity to assign protons from within and in between individual sugars. Additional
sensitivity was gained by repeatedly injecting OSCS contaminated UFH samples into
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the column. Since UFH eluted at 0.6 M NaCl and OSCS at 0.8 M NaCl, the UFH was
washed away after each injection and the OSCS was retained on the column. After 10
injections, the concentrated OSCS was eluted using 0.8 M NaCl and analyzed using
flow NMR to yield highly resolved spectra. HPLC-NMR has the potential to signal the
presence of impurities in UFH as well as identify them even when present in small
amounts [48].
Data from 1H-NMR has also proven useful in chemometric analyses [44,49-52].
Zang et al. utilized several techniques including principle component analysis (PCA)
and partial least squares discrminant analysis (PLS-DA). PCA is a method for reducing
large numbers of variables into a smaller number of “principle components” that account
for variation. The component accounting for the most variation in the sample is
designated PC1, while the next is PC2 and so on. When plotted in two or three
dimensions, enormously complex data sets can be analyzed using only a few variables.
PCA was able to sharply distinguish UFH and OSCS, but not DS. PLS-DA provided
even better seperation and could predict the presence of significant amounts of OSCS
in test samples with few misclassifications [51].
Two dimensional NMR and

13

C-NMR were instrumental in chemically identifying

the heparin contaminant in 2008. Seven peaks unique to OSCS were seen in the
contaminated UFH using

13

C-NMR while HMBC and HSQC identified oversulfated

monosaccharides [26]. Diffusion Ordered Nuclear Magnetic Resonance Spectroscopy
(DOSY) has been used to characterize LMWH and UFH formulations and distinguished
OSCS in LMWH [54,55]. DOSY makes use not only of 1H-NMR chemical shifts, but the
ditransaltional diffusion coefficient (Dt in m2/s) which is dependent on molecular weight
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rather than structural subtleties. Since OSCS chains are on average much larger than
LMWH, the presence of this contaminant is made most apparent. Such a technique
however, would be of little use if the contaminant were of a similar molar mass. Rudd et
al. used 2-D correlation spectroscopy to identify a variety of oversulfated polysaccharide
contaminants. This was done by subtracting standard UFH data sets from UFH samples
contaminated with OSCS, oversulfated dextran sulfate, and oversulfated agarose
sulfate, leaving the peaks characteristic of the contaminant available for unhindered
study [56]. NOESY has also been used to identify OSCS in UFH by taking into account
the environments of the ring protons [57].
The power of two dimensional NMR is such that it is able to provide accurate
structural information for GAGs far to complex for one dimensional NMR [36]. The chief
limitation is that the complexity of GAG spectra often requires highly skilled
interpretation. UFH and LMWH would prove much more difficult than a homogeneous
sample because of their heterogeneity. However, it would prove most useful for
confirming the identity of a contaminant that had been isolated especially when used
alongside mass spectrometry.
1.5 Other Spectroscopic Techniques in the Analysis of Heparins
Infrared (IR) and Raman spectroscopies have been used to highlight suspected
OSCS contaminated UFH lots using chemometric techniques [58]. Circular dichromism
is useful in distinguishing between GAGs as it measures the absorption of polarized
light in non-racemic samples [59]. The conformation of uronic acid in particular is
distinguishable since glucuronic and iduronic acids are opposite enantiomers. It has
also shown characteristic spectra of heparin when bound to different cations (Na+, Mg2+,
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K+, Ca2+, Mn2+, Cu2+, Fe3+) [60]. Since cations other than sodium may shift the N-acetyl
group of OSCS, NMR spectra, circular dichromism may be used in complimentary to
NMR in explaining deviant signal shifts [61]. Circular dichromism was recently reported
to give a clear differentiation of UFH and OSCS [62].
Jagt et al. published one of the most innovative heparin analysis protocols using
self assembling fluorescent receptors. The positively charged β-CD derivative heptakis[6-deoxy-6-(2-aminoethylsulfanyl)]-β-CD was derivatized with a number of amino and
guanadino groups and allowed to form an inclusion complex with various lithocholic acid
derivatives which bind with strong affinity. A number of lithocholic acid compounds
derivatized with a quinolinium flourophore were complexed with the functionalized CD.
The result was a complex with a dense positive charge and a fluorescent compound
sensitive to its local environment. This work yielded a complex showing a change in
fluorescence with OSCS that was far above UFH, LMWH, HS, DS, and CS. This work is
of great importance in that it proves that small to medium sized molecules or complexes
can distinguish between remarkably similar GAGs, which would be of great potential in
detecting specific contaminants. It also provides a simple pathway for designing
relatively complicated probes for the wider study of GAGs [63].
1.6 Electrophoretic Analysis of Heparins
Electrophoresis is a time tested approach for separating and studying heparin
and heparin-like GAGs. Preparative scale agarose gels was used to separate and
isolate four HS oligosaccharides [64]. Gradient polyacrylamide gel electrophoresis
(PAGE) is useful in resolving heparin species with a similar degree of polymerization but
differing internal structure and sulfation density [65]. In spite of the ubiquity of gel
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electrophoresis in laboratories, capillary electrophoresis (CE) is used more often with
GAGs as evidenced by the number of literature reviews in the last decade [66-68].
Several types of CE exist including capillary zone elcectrophoresis [66], capillary
isotachophoresis [69], micellar electrokinetic chromatography (MEKC) [70], capillary gel
electrophoresis

[71],

capillary

isoelectric

focusing

[72],

and

capillary

electrochromatography [73]. Of these, capillary zone electrophoresis (hereafter
designated simply as CE) and MEKC are most commonly employed in the analysis of
heparins because of their simplicity and effectiveness in seperating GAGs.[67].
In CE, a sample is injected into narrow, buffer filled, fused silica capillaries with
an inner diameter of 20-100 µm and an electric field is applied that will draw the
analytes toward the oppositely charged electrode as seen in figure 3. Figure 3a shows
CE with basic (pH~7) in normal polarity mode. Under these conditions, the silanol
groups on the wall are deprotonated, causing the cations of the buffer to coat to the wall
forming an immovable “stern” layer. Ions in the layer outside of this coating are
electrostatically pulled towards the cathode as a result of the zeta potential generated
by the electric field when applied to the layer. Because these cations drag their shells of
hydration, a powerful electroosmotic force is exerted in the direction of the cathode that
is able to pull even oppositely charged molecules toward the cathode, enabling the
separation of all ionic species and extending the length of the capillary. Under acidic
conditions, the silanol groups are largely protonated, suppressing the electroosmotic
force and allowing separation solely on the basis of charge-mass-ratio. Depending on
the charge of the analytes, either normal or reverse polarity can be used at low pH
(figure 3b) [67,74,75]. MECK utilizes is a form of CE in which a surfactant is added to

14

the buffer at a concentration that allows for the formation of micelles. These act as a
kind of stationary phase that differentially interacts with analytes, altering their mobility
and enabling their separation [70]. A maintained CE instrument in capable hands is able
to produce highly resolved electropherograms using only nanoliters of sample in a rapid
fashion [68].
Multiple CE protocols have been used to separate heparin disaccharides and
oligosaccharides. Pervin et al. separated eight heparin/heparin sulfate dissacharides
along with eight CS/UFH dissachardes with an unsaturated double bond and varying
sulfation levels using reverse polarity CE with 20 mM phosphate buffer, pH 3.48,
while13 heparin oligosaccharide standards ranging from 2-14 monosaccharides were
separated using MECK (10 mM sodium borate, 50 mM SDS, pH 8.8, normal polarity).
Baseline separation was achieved between the di- and tetrasaccharides with resolution
decreasing at longer chain lengths [76]. These results were consistent with that
obtained previously by Desai et al. for a mixture of 17 heparin chains ranging from di to
hexasaccharide. Compositional fingerprinting of several LMWHs were also achieved,
but only after significant depolymerization with heparin lyase enzymes [77]. Laser
induced fluorescence [78] and copper sulfate [79] have also been employed in the
detection of GAGs via CE.
The resolution of intact UFH and LMWH presents a major hurdle for CE because
of the phenomenal complexity of these mixtures since millions of GAG molecules are
present with only infinitesimal differences. Ramasamy et al. fingerprinted four LMWHs
using reverse polarity CE with both fused silica and neutral hydrophilic capillaries. While
there were noticeable differences between the products, most of the GAG remained in a
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relatively broad, featureless peak [80]. Patel et al. analyzed intact and decomposed
dalteparin and enoxaparin using reverse polarity CE. A comparison of two batches of
enoxaparin showed differences among the fine features of the electropherogram. While
enoxaparin resolution was better than that obtained by Ramasamy et al., the bulk of
enoxaparin remained locked in a featureless peak [81].
The heparin contamination crisis has incited great interest in electrophoretic
protocols in detection of heparin contaminants with special focus on OSCS. PAGE was
used to analyze heparins depolymerized by treatment with nitrous acid. Heparin is far
more sensitive to nitrous acid than most other GAGs including CS and OSCS because
of the presence of numerous N-sulfate groups (as opposed to N-acetyl groups). UFH
contaminated with 25% w/w OSCS was clearly distinguishable after nitrous acid
depolymerization with the small UFH fragments mostly migrating to the end of the gel.
The LOD of a 100 µg sample was approximately 0.5% w/w. Other GAGs such as DS,
OSDS, hyaluronic acid, dextran sulfate as well as other heparinoids were also readily
distinguishable from UFH, showing the utility of PAGE in detecting a variety of potential
contaminants [45]. Cellulose acetate plate electrophoresis was also employed in the
detection of OSCS and DS in UFH with a DS LOD of 0.4% [82]. The ubiquity of PAGE
in biochemical research makes it an attractive option for separation, but resolution is
dependent on the chemical decomposition of GAGs.
While PAGE and cellulose acetate electrophoresis are capable of separating
contaminants and impurities in UFH, neither is able to match the speed and resolution
of CE in this application. The FDA published a CE protocol that was able to detect
OSCS in UFH but only with partial resolution [83,84]. Though this protocol was later
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replaced by strong anion exchange HPLC (SAX-HPLC), a number of subsequent
methods were published with increasing efficiency and resolution [85]. Since then,
several new CE protocols have been published. Wielgos et al used 600 mM phosphate
pH 3.5 buffer with a 25 µm ID capillary with a total length of 64.5 cm. The result was a
nearly baseline resolved electropherogram with OSCS visible as a sharp just ahead of
UFH. Changing the counterion from sodium to lithium dramatically shortened the run
time by nearly 75% with an LOD below 0.1 % w/w of the total amount GAG mass.
Lithium based buffers have low conductivity relative to sodium and allow for higher field
strengths, yielding shorter separations. However, such stellar sensitivity was only
accomplished with extended path capillaries that are only compatible with CE systems
manufactured by Agilent [84]. A modified version of this method was used alongside 1
and 2 dimensional NMR to separate OSCS as well as oversulfated “tank bottom”
material considered to be waste by-products of the UFH purification process [26].
An improved method was published by Somsen et al. that resulted in the near
baseline resolution of OSCS from UFH using high molarity tris buffer with an LOD of
0.019 mg/ml for OSCS. The high concentration of tris resulted in substantial sharpening
of the OSCS peak, making it easy to distinguish from UFH and DS and the generation
of a very sharp peak. The method did not require an extended path length capillary and
used a CE system from Beckman without an extended path length capillary [86]. OSCS
and UFH were separated using a capillary loaded with polymerized β-cyclodextrin and
the polymer Tetronic® 1107 which contains two positive charges under acidic
conditions. The mixture of the two polymers creates a cationic pseudostationary phase
that sulfated polysaccharides will readily interact with. The LOD for the detection of
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OSCS was an astonishing 0.07% w/w of a 0.1 mg/ml UFH sample, the best yet
achieved with CE [87].
Since GAGs have low UV extension coefficients, derivitization with UV active
substances would enable enhanced sensitivity. Quantitative CE was used for the
resolution of galactosamine and glucosamine after acidic hydrolysis of a UFH/OSCS
mixture and the derivitization of the monosaccharides with anthranilic acid. Since UFH
and OSCS are composed of glucosamine and galactosamine sugars respectively, their
detection and quantitation allowed for distinguishing between two GAGs. However, this
was only possible if DS was previously degraded by chondroitinase since this would
also give galactosamine and potentially sound a false alarm [88]. Other sources of
galactosamine and glucosamine could potentially do the same.
1.7 Chromatographic Analysis of Heparins
Chromatography of glycosaminoglycans has long been used in resolving and
quantitatively

separating

heparin

and

related

polysaccharides.

Thin

layer

chromatography is capable of separating sulfated other GAGs from heparin [89]. Gel
filtration chromatography was used to fractionate nitrous acid depolymerised heparin
into long chains (MW > 3000), shorter chains such as tetrasaccharides, and
disaccharides [90]. Paper chromatography SAX-HPLC was employed in the separation,
quantification, and identification of tritiated disaccharides and oligosaccharides [91].
Strong anion exchange chromatography was used in purifying 14 oligosaccharides in
Pervin et al’s massive study [36]. Reverse phase ion pairing chromatography acquired
baseline separation of sugars ranging from disaccharide to tetradecasaccharide [92].
Hyphenated LC-MS is a an extremely effective tool for the characterization of GAG

18

mixtures since it can both separate and reveal structural information of GAGs [93-95].
Chromatography presents an attractive method for the separation of GAGs because of
the diversity of media and techniques, the ability to collecti the resolved fractions, and
the possibility of analysis via hyphenated techniques (LC-MS and LC-NMR) [47,96,97].
Due to their relative ease of analysis, chromatographic studies of disaccharide
and oligosaccharide composition derived from LMWH and UFH abound in the literature
[92,96]. Karamanos et al resolved all the major disaccharides of heparin and heparan
sulfate using reverse phase ion pairing HPLC with tetrabutylammonium and an
acetonitrile gradient. As expected, heparin contains a far greater proportion of trisulfated
disaccharide (68%) than heparan sulfate (8.7%). In comparison, the depolymerization
of dalteparin by heparin lyases yielded 84.2% trisulfated disaccharide [98]. UPLC
coupled to ESI-MS was able to separate and quantify heparin/heparan sulfate
disaccharides in under 5 minutes with heparin from porcine intestine, bovine intestine,
and bovine kidney yielding different disaccharide compositional profiles [99]. However,
few studies exist for the characterization of intact LMWH or UFH. Patel et al. developed
a powerful isocratic reverse phase HPLC technique capable of developing high
resolution fingerprints of LMWHs using both UV-vis and evaporative light scattering
detection (ELSD) under optimized conditions. Buffer concentration, pH, proportion of
acetonitrile, and the type and concentration of ion pairing agents were varied to optimize
separation. Incredibly, the reverse phase technique allowed for baseline separation of
many peaks in enoxaparin samples previously fractionated by size exclusion
chromatography. Such baseline resolution as yielded by this two stage separation is
typically very difficult to obtain and would facilitate LC-MS analysis of individual peaks,
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giving detailed insight into the elusive structural subtleties of LMWHs [100]. Doneanu et
al. produced the most highly resolved fingerprint of LMWH ever obtained using reverse
phase ion pairing UPLC coupled to quadrapole time of flight mass spectrometry. The
resolutive capabilities of UPLC and the analytical prowess of MS come together to yield
a total ion chromatogram of tinzaparin with over 50 peaks [101]. Both of these
techniques are capable of analyzing LMWHs in unprecedented detail, but are very
sensitive run buffer composition and may require the use of highly complex and
expensive equipment in the case of UPLC-MS.
Strong anion exchange HPLC has become one of the most effective means of
detecting oversulfated contaminants in UFH. Trehy et al. separated OSCS and DS from
UFH using a polymer based SAX-HPLC column and achieved a separation far superior
to the initial FDA method. Using UV detection, it is one of the most sensitive methods
for detecting OSCS published to date with an LOD of 6.2 µg/ml (0.03% of 20 mg/ml
UFH solution) [102]. The method was further developed to detect a variety of GAGS
including CS, hyaluronic acid, oversulfated hyaluronic acid, and OSDS with elution time
being largely dependent on the degree of sulfation of each GAG [103]. Weak anion
exchange chromatography has yielded similar results [104]. The protocol’s sensitivity
and resolution as well as the relative abundance of HPLC systems had led to the SAXHPLC method’s adoption in place of the CE protocol in the FDA and USP standards
[46].
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Capillary Electrophoretic Fingerprinting of Low Molecular Weight
Heparins

2.1 Background
A large number of biophysical techniques have been used to characterize
heparins. Gel electrophoresis, especially PAGE, has been developed to analyze
heparin polydispersity [105-108]. while chromatography, e.g., SEC or GPC, has been
developed to assess the molecular weight and oligomeric composition [106,108-114]
Other chromatographic techniques, e.g., reverse-phase, ion-pairing and strong anion
exchange, have been used to prepare heparin oligosaccharides as well as perform
oligosaccharide compositional analysis [36,92,115-120]. NMR spectroscopy has also
been used to assess saccharide composition and sulfation pattern, while being
especially useful for identifying certain non-native structures [41,121-123]. Twodimensional diffusion ordered spectroscopy has also been reported for detecting OSCS
in

LMWH

preparations

[124].

Recently,

tandem

liquid

chromatography-mass

spectrometry (LC-MS) has been exploited to perform sequence analysis on relatively
purified preparations of oligosaccharide [94,125-129]. Reverse- phase-ion-pairing ultra
high performance liquid chromatography-MS (UPLC-MS) yielded a spectacularly
resolved total ion chromatogram fingerprint of tinzaparin, though such hyphenated
methods require intricate equipment and skilled operators making difficult to implement
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for routine use [101]. While these results represent significant achievements in the
analysis of LMWH, the sheer complexity of these mixtures necessitate the further
development of robust, consistent, and high resolution techniques.
A technique that has gained widespread acceptance in LMWH and heparin
oligosaccharides analysis is capillary electrophoresis (CE). The earliest application of
CE for disaccharide compositional analysis of LMWHs [76-77,130] has now been
modified to protocols with much better sensitivity and resolving power [131-132]. A
significant improvement in sensitivity of CE detection has been pre-column labeling with
chromophores or fluorophores [78,133]. Further advances in CE applicability have been
the development of a tandem CE–MS system for elucidating structural information
[134].

Unfortunately,

these

powerful

approaches

work

on

essentially

pure

oligosaccharides, enzymatically depolymerized samples, or mixtures of smaller heparin
chains. Additionally, none of the methods is particularly suitable for assessing LMWH
preparations on a routine basis. More importantly, the absence of a rapid and simple
biophysical protocol for monitoring product quality is a major impediment for identifying
LMWHs complications. We sought to develop a CE method that can be employed in
high resolution fingerprinting of LMWH batches. Our hypothesis was that alkyl
polyamines would be able to interact with the highly sulfated heparin chains, resulting in
a highly resolved, formulation specific electrophoretic signature. We successfully
established low cost, extremely simple, and robust CE method to fingerprint intact
LMWHs that is especially useful for assessing product identity, quality, and batch-tobatch variability.
2.2 Experimental Procedures
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2.2.1 Chemicals and Electrophoresis Supplies
Enoxaparin (LovenoxTM, 40 mg syringes, Lot # 094480) and tinzaparin
(InnohepTM, 2 mL, 20,000U vial, Lot # DB1586) were purchased from VCU Medical
Center Department of Pharmacy Services, Richmond, VA. Two different Sigma LMWH
preparations (ID# H8537, lot #043K10261; and ID# H3400, lot 102K0673) from Sigma
(St. Louis, MO.) 2-Aminoacridone (AMAC) and sodium cyanoborohydride were also
purchased from Sigma (St. Louis, MO). Linear and cyclic polyamines were from either
Aldrich (St. Louis, MO) or Acros (Geel, Belgium) All other reagents/chemicals were
analytical grade and purchased from either Fisher (Fair Lawn, NJ) or Sigma-Aldrich (St.
Louis, MO). Fused silica capillaries were purchased from Beckman-Coulter (Fullerton,
CA).
2.2.2 AMAC-Labeling of Low Molecular Weight Heparins
The labeling of oligosaccharides at the reducing terminus with 2-aminoacridone
has been described extensively in the literature [35-37]. An essentially equivalent
protocol was followed herein. Briefly, clinically available enoxaparin and tinzaparin were
dialyzed extensively against deionized water (MWCO 500) to eliminate excipients and
lyophilized to obtain a solid. Sigma LMWH (ID# H3400) was obtained in solid form and
used as such. Solid LMWH (10–15 mg) and sodium cyanoborohydride (25 mg) were
dissolved in 560 µL of deionized water and mixed with a solution of AMAC (4 mg)
dissolved in 158 µL of 85% (v/v) acetic acid:DMSO. The mixture was allowed to
incubate at 37°C for 16 hours, then dialyzed against deionized water to remove free,
unreacted AMAC, and lyophilized. The solid so obtained was dissolved in deionized
water containing 10% DMSO (v/v) at 10 mg/mL and stored at -78°C until use.
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2.2.3. Capillary Electrophoresis of Low Molecular Weight Heparins
CE was performed using a 75 µm fused silica capillary (40 cm to the detector
window) installed in a Beckman-Coulter P/ACE MDQ capillary electrophoresis system.
A fresh capillary was activated using 5 min flushes each of 1 M NaOH, deionized water,
1 M H3PO4, and deionized water in sequence, while between each runs the flush time
was reduced to 30 sec with a final run buffer flush of 2 min. Under optimal fingerprinting
conditions, the stock solution of a LMWH was diluted nearly 10-fold with 10%
DMSO/water for injection into the capillary. CE run buffers used included 50 mM sodium
phosphate buffer at pH 2.3 and 100 mM ammonium formate buffer, pH 3.5. Each
contained 10% DMSO and appropriate resolving agent at the desired concentration.
Every CE run was performed with fresh 1 mL buffer vials. The temperature of the
capillary was maintained at 15°C and the run current was held constant at -75 µA under
optimal fingerprinting conditions. AMAC-labeled LMWH was injected for 15 sec at 1 PSI
giving a total injection amount of 150 ng and an injection volume of ~ 5–10 % of the total
capillary volume. Electrophoresis was monitored at 254 nm with a data collection rate of
4 Hz. Limit of detection (LOD) and limit of quantitation (LOQ) was taken to be 3 and 10
standard deviations above the average baseline in the region where LMWH was
located, as defined in the literature [135]. Deviations from these conditions are noted in
the text or figure captions. Unless specified otherwise, the Sigma LMWH used is ID#
H3400 and enoxaparin is lot #94480.
2.3 Results and Discussion
2.3.1 Linear Alkyl Polyamines Resolve Electrophoretic Profile of LMWHs
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Analysis of unfragmented, intact LMWHs is challenging because of polydispersity
and microheterogeneity, which are major impediments to resolution despite the power
of CE. Typically, a wide peak with few features is observed for intact LMWH samples in
normal as well as reverse polarity implying that the mixture of the millions of species
cannot be resolved (figure 2.1A) [136-138]. Recently, Ramasamy et al. [80] and Patel
et al. [81] attempted to fingerprint LMWH using a bare fused silica capillary under
reverse polarity conditions. Both groups reported an essentially broad LMWH peak
consisting of few shoulders in the peak front. To devise a more robust method for
assessing product identity and quality, we reasoned that the presence of certain
polycationic agents (figure 2.2), which modify the effective charge density of the highly
sulfated polymeric chains in a structure-dependent manner, will generate a
characteristic fingerprint pattern in CE of intact LMWHs.
Two clinically used LMWHs, enoxaparin (LovenoxTM) and tinzaparin (InnohepTM),
and one LMWH from Sigma were chosen. To aid detection, each LMWH was
reductively coupled with 2-aminoacridone (AMAC) on the reducing end. CE of AMAClabeled tinzaparin in 50 mM sodium phosphate buffer containing 10 % DMSO at pH 2.3
gave an unsymmetrical broad peak between 16 and 24 min (figure 2.1A), supporting
previous results on other LMWHs [80-81].

However, in the presence of 100 µM

tetraethylenepentamine (4EP), a linear molecule containing five basic nitrogens
separated by ethylene groups, the broad peak showed much longer migration time and
displayed multiple components. Enoxaparin also exhibited a peak with few features in
the absence of RA but was well resolved with 100 µM 4EP (figure 2.1B). Sigma LMWH
featured a number of distinguishable peaks between 20 and 26 minutes but none were
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baseline resolved. The addition of 50 µM 5EH transformed it into a highly resolved
fingerprint (figure 2.1C). Among the several buffers investigated, 50 mM sodium
phosphate (pH 2.3) and 100 mM ammonium formate (pH 3.5) (figure 2.3), provided
optimal resolution without compromising sensitivity and speed of analysis. These results
suggest that interaction with linear polyamines, which assume a polycationic nature in
strongly acidic conditions, dramatically alters the electrophoretic mobility of LMWH
chains. More importantly, the multiple peaks observed suggest that structurally different
LMWH chains are affected to different extents.
A wide ranging set of electrophoretic conditions were explored in acquiring useful
LMWH fingerprints. Temperature was varied from 15 to 35°C, voltage from 5 to 25 kV,
and capillary diameter from 50 to 75 µm. 15°C, -75 µA constant current, and 75 µM
capillary ID were chosen for the consistency of migration times, minimization of noise
and joule heating, and strong signal. 20 and 50 mM phosphate buffers ranging from pH
2.17 to 3.5 were explored with the 50 mM buffer being used for later runs. 20 mM
sodium citrate at pH 3.15 yielded LMWH peaks with excessive noise. Normal polarity
conditions were explored with ~ pH 7 phosphate and HEPES buffers without success.
Early in the project, it was noted that AMAC labeled LMWH tended to settle to the
bottom of the sample vial over time. This is largely caused by tendency of the
hydrophobic AMAC labels to aggregate in aqueous solutions, resulting in current
irregularities and inconsistent electropherograms (figure 2.4). Acetonitrile, methanol,
and DMSO were explored as sample additives to remedy this. A 10% DMSO additive
proved to be the most effective additive as it disrupted the aggregation caused by the

29

hydrophobic label. DMSO had a remarkably favorable effect on run to run consistency
and was used in all subsequent experiments.
2.3.2 Fingerprinting Pattern Depends on the Structure of the Resolving Agent
To assess whether the structure of the resolving agent affects the resolution of
LMWHs, we screened several cyclic and linear polyamines (figure 2.2). We reasoned
that the cyclic amines would present a dense cationic scaffold for possible interaction
with closely knit polyanionic domains in LMWHs, while the linear amines would favor
recognition of longer cationic domains. Also, linear polyamines containing either two-,
three- or four-carbon spacers between nitrogen atoms (figure 2.2) were investigated to
assess recognition of saccharide domains with different charge densities.
Figure 2.5 shows the electrophoretic profile of enoxaparin in 50 mM sodium
phosphate buffer, pH 2.3, in the presence of 125 µM concentration of either SPM, 4EP
or 5EH. As the number of nitrogen atoms increase (SPM < 4EP < 5EH), the resolving
agent is able to interact with enoxaparin better resulting in slower migration times.
Sigma LMWH behaves in a similar manner (figure 2.6). Tinzaparin also follows this
pattern, but reacts much more strongly with 5EH and weakly with SPM. This indicates
that tinzaparin is much more sensitive than enoxaparin and sigma LMWH to the charge
density on resolving agents (figure 2.7). This suggests that structural domains in the
chains of the two groups of LMWHs are different.
Although both 3ET and SPD (figure 2.2) contain four basic nitrogens, the former
weakly resolved enoxaparin, while SPD was virtually ineffective at concentrations as
high as 500 µM. Cyclic polyamines 3AN and 4AD were also completely ineffective.
Likewise, polybrene, a longer cationic polymer, was also not effective (figure 2.8). This
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suggests that fingerprinting is not a general property of all polyamines. More
importantly, optimal distribution of basic nitrogens and chain length is necessary for
good fingerprinting pattern.
The fingerprint resolution is highly sensitive to not only the structure of the
resolving agent, but also its concentration. More specifically, the linear resolving agents,
e.g., SPM, 4EP, and 5EH displayed a narrow range of concentrations that gave the best
resolution. For example, 125 µM 5EH baseline resolves the Sigma LMWH fingerprint
over a long period of time (figure 2.5), meaning that further increases in resolving agent
concentration would only extend the run time while providing little added resolution. The
same is not true for enoxaparin (figure 2.6), suggesting that the fingerprint pattern is
characteristic with respect to both the LMWH and the resolving agent.
It is important to note that several peaks are baseline resolved in the fingerprint
pattern with 5EH, especially in the region of 22 to 30 min (figure 2.5). It is likely that use
of laser-induced fluorescence would enhance sensitivity that would allow for the
decrease of LMWH concentration, potentially allowing for a fully baseline-resolved
fingerprint pattern. Baseline resolution also indicates that analysis of enoxaparin using
CE-MS may be possible under compatible run conditions (ammonium formate).
2.3.3 Different LMWHs Display Different Fingerprint Patterns
To assess whether the fingerprint pattern is characteristic of individual LMWHs,
we compared CE runs of enoxaparin, tinzaparin and Sigma LMWH in the presence of
50 µM 4EP at pH 2.3 (figure 2.9). Each LMWH shows a characteristic fingerprint
pattern defined primarily by the extent of interaction with the resolving agent. Whereas
enoxaparin displays prominent peaks at 25 and 30 min, Sigma LMWH is devoid of the
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pattern at ~30 min. In contrast, both these patterns are absent in tinzaparin. Also,
tinzaparin displays much lower resolution than enoxaparin and Sigma LMWH.
Equivalent results were observed for other resolving agents including SPM and 5EH
(not shown). These fingerprint patterns are highly reproducible with notably low intraday (figure 2.10A). The variability in migration time was investigated in more detail for
several resolving agents by selecting a prominent peak from the sample (data not
shown). It was observed that the protocol yields an average migration time variability of
21 seconds, which suggests the possibility of automated comparative analysis. With
respect to inter-day reproducibility, the overall pattern and migration time of two
enoxaparin fingerprints appeared consistant (figure 2.10B), though a more detailed
analysis would involve several sets of runs over a period of weeks. In the absence of
resolving agent, the electrophoretic response displayed good linearity over a wide range
concentration with a measured limit of detection and quantitation of 140±23 and 290±47
µg/mL, respectively (see figure 2.11 and Table 2.1). These limits are not as good as
expected and it is likely that the use of higher sensitivity chromo- or fluorophores or
laser-induced detection may improve sensitivity. Overall, the results indicate that
fingerprinting pattern, especially with multiple resolving agents, and the stability of
electropherograms could greatly help identify and quantitate individual LMWHs. We
believe that the quality and consistency of these fingerprints will prove useful in batch to
batch analysis of LMWHs.
2.4 Conclusions and Significance
Our results show that LMWHs can be readily fingerprinted using a simple
capillary electrophoretic protocol. The protocol uses readily available chemicals, is
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rapid, and is highly reproducible in producing distinctive fingerprint patterns. It can be
exploited for identifying intact LMWHs, monitoring product quality and for checking
batch to batch variability. Although the resolution achieved using a single resolving
agent is sufficient, the power of fingerprinting might be expanded with multiple resolving
agents or with a mixture of resolving agents. This is especially important considering
that a number of LMWHs are being rapidly introduced in the world market [139].
Agent 5EH was found to be especially good at resolving enoxaparin and Sigma LMWH
into several baseline-resolved peaks. It is likely that full baseline-resolution will become
possible with selected modifications to the protocol, e.g., use of laser-induced
fluorescence. This will enable detailed sequence analysis of nearly all LMWH chains
through tandem CE-MS/MS approaches. A major advantage of the MS-based analysis
is the possibility of identifying the proportion of LMWH chains containing the high-affinity
pentasaccharide sequence, which governs anticoagulant activity in vivo [140]. Likewise,
it is likely that the CE-MS/MS approach will become useful in deciphering heparin
structure – activity relationships in areas other than coagulation.
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Table 2.1: Limit of Detection and Limit of Quantitation for Enoxaparin.
Absorbance (× 106 )
(AU)

Concentration
(µg/mL)

Average Noise

261 ± 42a

-

Limit of Detection

387 ± 62b

143 ± 23c

Limit of Quantitation

681 ± 109d

290 ± 47c

a

Several blank runs were recorded and the noise in the baseline corresponding to the
enoxaparin peak was analyzed to obtain the average noise height and its standard
deviation. bRepresents 3×SD over the baseline. cObtained using the linear regression
described in Figure 11. dRepresents 10×SD over the baseline.
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Figure 2.1: Linear alkyl polyamines turn nearly featureless peaks into highly
resolved fingerprints. A) Tinzaparin with and without 100 µM 4EP, B) Enoxaparin with
and without 100 µM 4EP, and C) Sigma LMWH with and without 50 µM 5EH. Peaks
marked with “x” are sudden disturbances due to bubble formation during the
electrophoretic run.
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Figure 2.3: Enoxaparin is effectively fingerprinted by 100 µM 4EP in 100 mM
ammonium formate.
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Figure 2.4: Back to back unlabeled Sigma LMWH (H8537) runs. Buffer contained 49
µM SPM with no DMSO in the sample and buffer. Run conditions: 20 mM sodium
phosphate pH 3.3, 10 kv constant voltage, 25°C constant temperature.

39

Absorbance at 254 nm

0.01
0.008

SPM

0.006

4EP
5EH

0.004
0.002
0
0

10

20

30

40

50

60

Time (min)
Figure 2.5: Sigma LMWH fingerprints with 125 µM SPM, 4EP, and 5EH
respectively. Peaks marked with “x” are sudden disturbances due to bubble formation
during the electrophoretic run.
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Figure 2.6: Enoxaparin fingerprints with 125 µM SPM, 4EP, and 5EH respectively.
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Figure 2.7: Tinzaparin fingerprints with 125 µM SPM, 4EP, and 5EH respectively.
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Figure 2.8: Sigma LMWH (H8537) with two concentrations of polybrene buffer
additive. Run conditions: 20 mM sodium phosphate pH 3.5 with 10% DMSO, 15 kv
constant voltage.
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Figure 2.9: Enoxaparin, Sigma LMWH, and tinzaparin fingerprints with 125 µM
4EP. Peaks marked with “x” are sudden disturbances due to bubble formation during
the electrophoretic run.
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Figure 2.10: A) Same day runs of Sigma LMWH with 125 µM SPM. B) Different
day runs of enoxaparin with 75 µM 5EH. Peaks marked with “x” are sudden
disturbances due to bubble formation during the run.
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Figure 2.11: Absorption vs. enoxaparin concentration plot demonstrating the
dependence of peak height on the amount of labeled LMWH. The equation
obtained from the linear regression was used to calculate the LOD and LOQ (see Table
1).
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Resolution of Full Length Glycosaminoglycans

3.1 Introduction
The fingerprinting of LMWHs suggested the possibility of the same with longer
GAGs such as UFH. The sheer complexity of these mixtures makes their separation
and characterization a difficult endeavor. Yet, the development of a reliable, high
resolution fingerprinting protocol would be highly useful for a number of reasons. First,
UFH is taken from animal sources, meaning that their synthesis may be affected by the
environmental conditions in which the host lived. Fingerprinting would allow for
detecting variation among lots of heparin and ensuring a consistent patient response
[2]. Second, UFH has pharmacological properties far beyond its anticoagulant activity
due to interactions with numerous proteins [141]. High resolution fingerprinting of UFH
would aid in the discovery of specific sugar sequences responsible for this activity.
Finally, the OSCS-heparin contamination crisis has highlighted the necessity for
techniques capable of detecting unwanted contaminants as numerous protocols have
appeared in the literature [26,48]. A full discussion of the issues surrounding the
characterization of UFH can be found in Chapter 1.
This chapter details our efforts to use the linear polyamines to resolve and
fingerprint UFH and CS.

Conditions explored included wide variations in sample

concentrations, buffer salt, and additives. Novel resolving agents were also explored
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including poly amino acids, protamine sulfate, polybrene, and massive polyamidoamine
dendrimers. These results were expected to provide insight into the nature of the
interaction between positively charged small molecules and complex GAGs. This in turn
will prove useful structural and functional analysis of heterogeneous polysaccharide
mixtures.
We also explored the potential of our resolving agents in identifying OSCS
contamination of UFH. As detailed in chapter 1, this is important for the purity of the
drug and most importantly the safety of patients. While other CE protocols have been
developed, we have found that 5EH provides a wider separation of the two than has
been published. With improvements in sensitivity, this may become a useful technique
in the analysis of UFH purity.
3.2 Methods
3.2.1 Materials
UFH lot 405492 from Abraxis Pharmaceuticals (Schaumburg, IL) was purchased
from the Department of Pharmacy Services at Virginia Commonwealth University Health
Systems. UFH lot 026K1554 was purchased from Sigma-Aldrich (St. Louis, MO). 2Aminoacridone (AMAC), 2-aminoanthraquinone, 2-amino-3-hydroxyanthraquinone, CS
(chondroitin sulfate A, lot # 038K1276), Polyamidoamino dendrimer generation 0
(PAMAM#0), generation 1 (PAMAM#1), polybrene, protamine sulfate, pyridine, sulfur
trioxide pyridine,and dibasic sodium phosphate were purchased from Sigma-Aldrich (St.
Louis, MO). DMSO and hydrochloric acid was purchased from Fisher Scientific
(Pittsburgh, PA). Pentaethylenehexamine (5EH), tetraethylenepentamine (4EP), and
spermine (SPM) were purchased from Acros Organics (Geel, Belgium). Fused silica
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capillary (75 µm inner diameter) was purchased from Microsolv Corporation (Eatontown,
NJ). Sodium cyanoborohydride and decamethonium iodide were purchased from TCI
America (Portland, OR). G-10 was purchased from GE-healthcare (United Kingdom).
3.2.2 Labeling of GAGs
A representative labeling procedure involved dissolving 100 mg of CS in 800 µL of high
purity water and 8 mg of AMAC in 800 µL of a 17:3 solution of water and incubation
DMSO/Acetic Acid. The AMAC was then added to the dissolved UFH and the solutions
were allowed to incubate at 37°C for 18-24 hours, followed by the addition of 320 mg of
sodium cyanoborohydride in 350 µL water for approximately 6 more hours. The free
AMAC was filtered out by a sephadex G-10 column and liopholyzed. Anthraquinone
(AMAQ) based labels underwent a similar procedure to AMAC. UFH was labeled by a
similar procedure to CS.
3.2.3 Oversulfation of CS
OSCS was synthesized from CS previously labeled with 2-aminoacridone. in a
manner similar to that reported in the literature [43]. Briefly, AMAC-labeled CS was
converted to a triethylamine salt using a AG 50W-X8 cation exchange column followed
by titration to pH 5 with triethylamine. 100 mg CS and 2.5 g sulfur trioxide – pyridine
complex were dissolved in 8 ml of anhydrous DMF and stirred at 50°C for 1 h. The
sodium salt was regenerated by precipitation by adding cold ethanol saturated with
sodium acetate as described in the literature [43].
3.2.4 Capillary Electrophoresis
CE was performed on a Beckman-Coulter P/ACE MDQ capillary electrophoresis
instrument using 75 and 100 µm inner diameter fused silica capillaries. The capillary
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was rinsed with 0.5 M sodium hydroxide, water, 0.5 M phosphoric acid, and water for 2
minutes each at the beginning of each round of CE runs and was briefly rinsed
periodically during the day afterwards. The exact run conditions often varied between
experiments and are noted in the caption of each figure or in the text.
3.3 Results
3.3.1 Fingerprinting of Unfractionated Heparin.
Initial efforts to develop high resolution fingerprints using the same conditions as
LMWH as described in chapter 1 were unsuccessful.

Figure 3.1 shows

electropherograms of 30 mg/ml Sigma-Aldrich UFH with increasing concentrations of
5EH. 25 µM 5EH merely resulted in the compression and sharpening of the main peak
body, but higher concentrations produced a scattered peak pattern. The peaks acquired
resembled the build up of air bubbles in the capillary due to joule heating, though the
capillary temperature was set at 15°C. As the 50 µM runs indicate, the peaks are not
reproducible from run to run, meaning they are not useful as fingerprints (figure 3.1b).
The peaks seen did not translate into a usable fingerprint. Raising the concentration of
5EH to 150 µM further increases the number of peaks indicating that there is a vigorous
interaction taking place but in an erratic manner. Decreasing the concentration of UFH
to 3 mg/ml of Sigma UFH resulted in a noticeable change in the sensitivity of the GAG
to 5EH, though it was not suitable as a fingerprint. 20 µM 5EH provided numerous
peaks comparable to what 100-200 µM 5EH would do at much higher concentrations of
UFH as displayed in figure 3.2. This indicates that there is likely a large number of sites
for 5EH to saturate on UFH. A batch of clinically used UFH made by Abraxis
Pharmaceuticals yielded the same results (not shown). Increasing the buffer
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concentration from 20 to 50 mM sodium phosphate and reducing the concentration of
Sigma UFH to 1 mg/ml yielded results was expected to have a moderating effect on
5EH binding and further decrease the number of possible sites as this was considered a
possible reason for the erratic profiles. However, results were similar to that obtained
previously though with greater sensitivity to 5EH as seen in figure 3.3. Since
aggregation was a major problem in developing consistent LMWH fingerprints, it was
thought that increasing the DMSO concentration by 50-100% would prevent
aggregation that may occur with UFH. 100 mM NaCl was added to the buffer as the
DMSO tended to suppress the voltage at constant current. The addition of DMSO
eliminated the peaks (figure 3.4). The addition of 20 mM triethylamine to 30 mM
phosphate buffer with 10% DMSO produced a multi-featured fingerprint of 15 mg/ml
Abraxis UFH in the presence of 50 µM 5EH (figure 3.5). It was hoped that adding large
amounts of triethylamine would have a stabilizing effect on the polyamine UFHinteraction, but it did not aid in developing useful fingerprints as the profiles acquired
were not reproducible.
Buffer systems based on salts other than sodium phosphate were also explored
as changes the interactions of different electrolytes with both 5EH and UFH could affect
how the two interacted with each other. 10 mg/ml of Sigma Aldrich UFH was not
successfully fingerprinted when pH 2.75 50 mM sodium citrate. Changing the organic
additive to 5% methanol yielded similar results (not shown). 100 mM ammonium
formate pH 3.46, while successfully used to fingerprint LMWH in chapter 2 (figure 2.3)
yielded fingerprints resembling that of sodium phosphate buffer (not shown).
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5EH proved unable to predictably fingerprint UFH under any set of run conditions
performed in a manner similar to those used for LMWH. A novel approach to this
problem was needed. 25 µM 5EH was incubated with the Abraxis UFH sample
overnight at room temperature to slow and stabilize the 5EH-UFH equilibrium. CE was
then performed with 25 µM 5EH in the buffer in typical fashion. The result was the most
consistent UFH electropherograms acquired, with three back to back runs displaying
notable similarities (figure 3.6). Even so, they did not display the reproducibility needed
for a fingerprint useful for quality control and assurance. Runs at controlled temperature
incubations of 37°C yielded similar results.
The failure of 5EH as an effective agent prompted the exploration of other
polycationic compounds as means of resolution. 4EP and SPM were successful with
LMWH but failed with UFH, with 4EP profiles resembling that of 5EH and SPM showing
no resolutive capability (figure 3.7). It was thought that longer polycationic compounds
would interact differently with UFH than 5EH, creating a stable interaction and a
reproducible fingerprint. Poly-L-lysine with an average molecular weight of 4200 gave
inconsistent results, but often resulted in a large amount of peak compression with little
resolution (figure 3.8). Poly-L-lysine mixtures of higher average molecular weight along
with poly-L-arginine mixtures proved useless as resolving agents. The quaternized,
polydisperse mixtures polybrene and protamine sulfate were explored in varying mixed
proportions. Like the overnight 5EH incubation results, this showed a somewhat higher
run to run consistency than usual, but failed to develop useful fingerprints (figure 3.9).
PAMAM#1 looked to be a promising agent simply because of its large size and
abundance of charges like polybrene, but was also a homogeneous compound. Results
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were very similar to 5EH in that the profile was not the same from one run to the next
(figure 3.10-3.11).
3.3.2 Fingerprinting of Chondroitin Sulfate
Like heparin, CS is a glycosaminoglycan with many physiologic actions and an
astonishingly high degree of heterogeneity and polydispersity [6,142]. Thus, CS was
expected to behave similarly to UFH in the presence of polyamines. This however, was
not the case as 5EH displayed little ability to interact with CS at 200 µM and had no
resolutive capabilities with 800 µM 4EP (not shown). CS has a lower density of sulfate
groups when compared to UFH (0.95 vs 2.4 sulfates per disaccharides, respectively). It
is likely that there is not enough sulfate groups present on CS to effect the same
response to 5EH that UFH does [143]. Poly-L-lysine provided resolution of CS (figure
3.12), but this could not be reproduced. Difficulties were even more prominent with
polybrene. The most reproducible electrophoretic profiles for CS were obtained using
PAMAM #1. Figures 3.13 show that PAMAM #1 was able to generate surprisingly
reproducible profiles of CS at 15 µM. Unfortunately, this was not consistent from day to
day as subsequent runs lacked the resolution and repeatability desired for a fingerprint.
As with UFH, no set of conditions explored resulted in repeatable, high resolution
fingerprints of CS.
3.3.3 Separation of Oversulfated Chondroitin Sulfate from Unfractionated Heparin
While several CE protocols available for detecting oversulfated contaminants in
UFH [45,46,84], we sought to use linear alkyl polyamines to improve on their resolution.
Initial results CE results were confirmatory of the higher degree of sulfation pattern on
OSCS when compared to CS (figure 3.14a-b). Both OSCS and UFH displayed affinity
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for 40 µM 5EH at a sample concentration of 20 mg/ml, but yielded dramatically different
profiles. OSCS showed a compressed peak that migrated very little, but UFH displayed
its characteristic noisy pattern. Since the two peak bodies came out at different times, it
was thought that UFH and OSCS would be easily separated in a mixture (figure
3.14c,e). However, this was not the case as UFH-OSCS mixtures of varying proportions
were inseparable. In fact, only a single peak body was present where there should have
been two of them (figure 3.15). The addition of 5EH to a mixture of UFH and OSCS
likely causes aggregation of the two polysaccharides. However, upon sharly reducing
the sample concentration, the results are dramatically different.

Figure 3.16a-b

displays UFH and OSCS electropherograms eluting separately as previously seen, with
both GAGs having a sample concentration of 0.5 mg/ml and 15 µM 5EH in the run
buffer. When combined to form a 1 mg/ml GAG mixture of 50% UFH and 50% OSCS, a
wide separation of 10-15 minutes separation was observed (figure 3.16c). In
comparison to other CE protocols, none have shown such a separation between OSCS
and UFH. It is notable that the UFH migrated faster when mixed with OSCS than when
alone. It is possible that OSCS sequesters a large proportion of 5EH and cause UFH to
come out sooner than otherwise due to the reduced availability of the resolving agent.
However, the low concentration of each GAG did not allow aggregation as seen with 20
mg/ml GAG. Resolution time was further shortened by applying 0.3 PSI forward
pressure and switching the polarity from normal to reverse (figure 3.16d). This allows
for OSCS to come out as normal while forcing UFH to come out in a narrow band of
peaks. Unfortunately, the method suffered from an inadequate limit of detection. A 1
mg/ml solution with 10% OSCS displayed an irregular signal from run to run. Less than
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10% OSCS showed little if any signal. The total GAG concentration was increased to 2
mg/ml to remedy this, but resulted in a noticable reduction in resolution (figure 17). It is
likely the case that the increased GAG concentration was causing an aggregation
similar to that of the 20 mg/ml sample in figure 3.15. If the concentration of the GAG
were further increased, OSCS and UFH would likely become indistinguishable.
3.4 Discussion
The failure of UFH to be fingerprinted under any circumstances presents a
puzzling problem. Why do LMWHs yield useful fingerprints in the presence of resolving
agents while UFH does not? The answer most likely involves an abnormally high
number of specific binding sites. As chapter 4 discusses in detail, enoxaparin’s profile is
largely due to the interaction of 5EH with high affinity sites on the GAG chain. UFH’s
affinity for 5EH is likely so high that a dynamic equilibrium sets in, with polyamines
forming complexes with multiple UFH chains. This prevents the formation of a normal,
reproducible fingerprint. Further evidence is seen in figures 3.1-3.3, where decreasing
the UFH sample concentration 10-fold increases its response to 5EH in a noticeable
manner. This indicates that whatever binding sites are available on UFH are not
completely saturated at the concentrations of resolving agents used for fingerprinting.
Further evidence of this phenomenon is clearly seen in the OSCS-UFH studies where
the two components are only resolvable when their concentration is low. At higher
concentrations, polyamines act as a “glue” that holds them together. It is highly likely
that such aggregation is occurring between UFH molecules in the presence of 5EH
even when OSCS is absent.
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Alternatively, it is possible that the “noise” seen in most profiles is due to joule
heating resulting from the high sulfate density of UFH and the concentration of
polyamines. However, the data suggests otherwise. The LMWH trials in chapter 2 do
not show such noisy profiles though they also contain a high density of sulfates. The
fact 20 and 50 mM sodium phosphate buffers showed similar peak patterns indicates
that higher ionic strength is not the cause of the irregular profiles (figures 3.2-3.3).
Rather, it is due a tighter interaction of UFH with the resolving agents.
The best solution to the problem of UFH would be to use laser-induced
fluorescence detection as this is much more sensitive than UV. This would allow the
concentration of UFH to be reduced dramatically, possibly eliminating aggregation and
reducing the number of binding sites. Such improvements would also allow for lowering
the limit of detection of OSCS, making it a potentially viable method.
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Figure 3.1: Same day fingerprints of UFH in the presence of 5EH. A) 0 and 25 µM
5EH; B) 4 repeated runs of 50 µM 5EH; C) 150 µM 5EH. Sample: 30 mg/ml Sigma UFH
026k1554 in 10% DMSO; Buffer: 20 mM sodium phosphate 10% DMSO pH 2.3; 254 nm
detection; Injection: 15 seconds@1psi; temperature: 15°C; Separation: 110 µA
Capillary: 100 µm ID.
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Figure 3.2: Same day fingerprints of reduced concentration UFH in the presence
of 20 µM 5EH. Sample: 3 mg/ml Sigma UFH 026k1554 in 10% DMSO; Buffer: 20 mM
sodium phosphate 10% DMSO pH 2.3; 254 nm detection; temperature: 15°C; Injection:
15 seconds@1psi; Separation: 110 µA; Capillary: 100 µm ID.
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Figure 3.3: Same day fingerprints of 1 mg/ml UFH in the presence of 5EH. A) 3 µM
5EH, B) 6 µM 5EH. Sample: 1 mg/ml Sigma UFH 026K1554 in 10% DMSO; Buffer: 50
mM NaPi pH 2.3; 254 nm detection; Injection: 10 seconds@1.5psi; temperature: 15°C;
Separation: 110 µA; Capillary: 100 µm ID.
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Figure 3.4: Same day fingerprints of 3 mg/ml Sigma UFH in 15 µM 5EH with
differing buffer compositions. A) 20 mM sodium phosphate pH 2.3 10% DMSO, B)
20 mM sodium phosphate, 100 mM NaCl, 17.5% DMSO. Sample: 3 mg/ml Sigma UFH
026k1554 in 10% DMSO; 254 nm detection; Injection: 15 seconds@1psi; Separation:
110 µA; Capillary: 100 µm ID.
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Figure 3.5: An attempt to fingerprint UFH with 50 µM 5EH and 20 mM
triethylamine. Sample: 15 mg/ml Abraxis UFH 405492 10% DMSO; Buffer: 30 mM
sodium phosphate 20 mM triethylamine pH 2.3 10% DMSO; 254 nm detection;
Injection: 10 seconds @ 1.5 psi; temperature: 15°C; Separation: 10 kV; Capillary: 75 µm
ID.
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Figure 3.6: UFH sample that was incubated with 25 µM 5EH overnight. Three
consecutive runs were performed. Sample: 10 mg/ml Abraxis UFH 405492 10% DMSO
25 µM 5EH; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm detection;
Injection: 8s@1psi; temperature: 25°C; Separation: 10 kV; Capillary: 75 µm ID.
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Figure 3.7: SPM and 4EP used in the resolution of UFH. A) 50 µM SPM, B) 50 µM
4EP. Sample: 2 mg/ml Sigma UFH 026K1554 10% DMSO; Buffer: 50 mM sodium
phosphate pH 2.3 10% DMSO; 254 nm detection; Injection: 8 seconds@1psi;
temperature: 15°C; Separation: 100 µA; Capillary: 75 µm ID.
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Figure 3.8: Attempt to resolve UFH with poly-L-lysine (mean MW: 4200). A) 2.5 µM
PLL, B) 5 µM PLL, C) 7.5 µM PLL, D) 10 µM PLL. Sample: 10 mg/ml Abraxis UFH
405492 10% DMSO 25 µM 5EH; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO;
254 nm detection; Injection: 10 seconds@1.5psi; temperature: 25°C; Separation: 10 kV;
Capillary: 75 µm ID.
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Figure 3.9: Attempt to resolve UFH a mixture of polybrene and protamine. A) No
agent, B) 15 µg/ml polybrene+5 µg/ml protamine #1 C) 15 µg/ml polybrene+5 µg/ml
protamine #1. Sample: 20 mg/ml Abraxis UFH 405492 10% DMSO; Buffer: 50 mM
sodium phosphate pH 2.3 10% DMSO; 254 nm detection; Injection: 8 seconds@1psi;
temperature: 15°C; Separation: 10 kV; Capillary: 75 µm ID.
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Figure 3.10: The structure of polyamidoamide #1 (PAMAM #1).
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Figure 3.11: Attempt to resolve UFH with PAMAM#1. A) No agent, B) 40 µM
PAMAM#1, C) 100 µM PAMAM#1. Sample: 15 mg/ml Abraxis UFH 405492 10%
DMSO; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm detection;
Injection: 10 seconds@1.5psi; temperature: 15°C; Separation: 15 kV; Capillary: 75 µm
ID.
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Figure 3.12: Attempt to resolve CS with poly-L-lysine (average MW: 4200) and
polybrene. A) No agent, B) 25 µM poly-L-lysine, C) 25 µg/ml polybrene. Sample: CS
038K1276 10% DMSO; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm
detection; Injection: 8 seconds@1 psi; temperature: 15°C; Separation: 14 kV; Capillary:
75 µm ID.
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Figure 3.13: Attempt to resolve CS with back to back runs with 15 µM PAMAM #1.
A) 15 µM PAMAM #1, B) 15 µM PAMAM #1. Sample: CS 038K1276 10% DMSO;
Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm detection; Injection: 8
seconds@1 psi; temperature: 15°C; Separation: 14 kV; Capillary: 75 µm ID.
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Figure 3.14: A comparison of CS, OSCS and UFH. All GAGs labeled with
athraquinone and dissolved in 10% DMSO for CE. A) 9 mg/ml CS with no agent, B)
10 mg/ml OSCS with no agent, C) 20 mg/ml OSCS with 40 µM 5EH, D) 20 mg/ml Acros
UFH lot B0126660 with no agent, E) 20 mg/ml Acros UFH lot B0126660 with 40 µM
5EH. Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 300 nm detection; Injection:
8 seconds@1psi; temperature: 15°C; Separation: 85µA ; Capillary: 75 µm ID.
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Figure 3.15: A comparison of three mixtures of OSCS and UFH. All GAGs labeled
with 2-aminoanthraquinone and dissolved in 10% DMSO to a combined concentration
of 20 mg/ml for CE. UFH lot: B0126660. A) 20% UFH 80% OSCS, B) 60 % UFH 40%
OSCS, C) 80% UFH, 20% OSCS. Buffer: 50 mM sodium phosphate pH 2.3 10%
DMSO; 300 nm detection; Injection: 8 seconds@1psi; temperature: 15°C; Separation:
85µA ; Capillary: 75 µm ID.
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Figure 3.16: A comparison of UFH, OSCS, and a mixture of the two. All GAGs
labeled with 2-aminoacridoine and dissolved in 10% DMSO. UFH lot: 026K1554. A) 0.5
mg/ml UFH, 15 µM 5EH B) 0.5 mg/ml OSCS, 15 µM 5EH , C) 1 mg/ml – 50% UFH, 50%
OSCS, 15 µM 5EH. D) 1 mg/ml – 50% UFH, 50% OSCS, 15 µM 5EH w/ 0.3 PSI forward
pressure and normal polarity switch at 30 minutes. Buffer: 50 mM sodium phosphate pH
2.3 10% DMSO; 254 nm detection; Injection: 8 seconds@1psi; temperature: 15°C;
Separation: 85µA ; Capillary: 75 µm ID.
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Figure 3.17: Back to back electropherograms of a 2 mg/ml GAG solution with 75%
UFH and 25% OSCS in the presence of 20 µM 5EH. Buffer: 50 mM sodium phosphate
pH 2.3; 254 nm detection; Injection: 8 seconds@1psi; temperature: 15°C; Separation:
85 µA; Capillary: 75 µm ID.
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Insights into the Interaction of Linear Polyalkylamines with Low
Molecular Weight Heparins and Glycosaminoglycans Using Capillary
Electrophoresis
4.1 Introduction

GAGs are unparalleled among biomolecules in terms of their massive structural
complexity, intricate and variable biosynthetic preparation, and astonishingly difficult
structural, biochemical and biophysical characterization. This difficulty has inspired a
large number of biophysical methods for analysis of different GAGs [68]. Further, a
number of protocols relying on HPLC [100,102], NMR [45,55,144], CE [86,88], and a
combination of techniques [51] have been developed for detecting UFH contaminants.
We described a CE protocol that fingerprints LMWHs in chapter 2. Linear polyamines
(figure 2.2) were used as resolving agents to produce fingerprint patterns in reverse
polarity, open-tube CE from essentially featureless and unresolved profiles. These
fingerprints were characteristic of the LMWH being analyzed, which afforded a major
advance in profiling differences among LMWHs could prove suitable in assessing the
batch-to-batch variability.
In this chapter, we address the question of why linear polyalkylamines are
effective in fingerprinting LMWHs and whether these could be used in profiling other
GAGs. Our work suggests that CE profile of GAGs such as DS, CS, OSCS and heparin
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in the presence of polyalkylamines can be used to understand the composition of these
complex mixtures. This property arises from differential recognition of micro-structures
present in GAGs, which enable high affinity recognition of highly sulfated chains. These
results are important because small molecule probes of GAGs are critically needed to
aid in structural and functional analysis.
4.2 Methods
4.2.1 Materials

Enoxaparin (Lovenox, 40 mg syringe Lot # 09438) was purchased from the
Department of Pharmacy Services at Virginia Commonwealth University Health
Systems. 2-Aminoacridone (AMAC), CS (chondroitin sulfate A, lot # 038K1276), DS (lot
# 118K1217), and dibasic sodium phosphate were purchased from Sigma-Aldrich (St.
Louis, MO). DMSO and hydrochloric acid was purchased from Fisher Scientific
(Pittsburgh, PA). Pentaethylenehexamine (5EH), tetraethylenepentamine (4EP), and
spermine (SPM) were purchased from Acros Organics (Geel, Belgium) and used as
received. Fused silica capillary (75 µM inner diameter) was purchased from Microsolv
Corporation (Eatontown, NJ). Sodium cyanoborohydride and decamethonium iodide
were purchased from TCI America (Portland, OR). Oligosaccharide species were
purchased from Idruron (Manchest, UK).
4.2.2 Chromogenic Labeling of GAGs

AMAC labeling of enoxaparin was performed in a manner similar to that reported
in the literature so as to enable detection of polymeric chains [145]. Briefly, LMWH (40
mg) was dissolved in 250 µL water, while AMAC (10 mg) was dissolved in 400 µL of
DMSO:acetic acid (17:3 v/v). The two solutions were mixed, followed by the addition of
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200 µL of sodium cyanoborohydride (100 mg) in water. The reaction was allowed to
proceed for 16 hours at 37°C. The AMAC-labeled enoxaparin from the reaction mixture
was purified via a G-10 column, the fractions lyophilized, and solid stored at 4°C until
use. Samples for electrophoresis were dissolved in 10% DMSO and water just before
analysis. Similar procedures were used for preparing AMAC-labeled UFH, CS, DS, and
OSCS.
4.2.3 Capillary Electrophoresis

CE

was

performed

using

a

Beckman-Coulter

P/ACE

MDQ

capillary

electrophoresis system using a 50 cm long fused silica capillary (40 cm to detector
window, 75 µ ID). The electrophoresis buffer was composed of 50 mM sodium
phosphate, pH 2.3, containing 10% DMSO. The capillary was flushed with
electrophoresis buffer for two minutes, followed by injection of the analyte for 8 seconds
at 1 psi. AMAC-labeled GAGs were dissolved in 10% DMSO to prevent aggregation.
Separations were performed at either constant current (~85 µA) or voltage (~10 kV),
temperature of 15°C and monitored at a wavelength of 254 nm. The capillary was
periodically flushed with 0.5 N NaOH, 0.5 M H3PO4, and deionized water to maintain its
resolution capability. GAG fingerprints were acquired with SPM, 5EH, 4EP and DM
(figure 2.2, 4.1). For the enoxaparin affinity studies, typically, 8-13 different
concentrations of each resolving agent were studied within a day. Each concentration
was studied at least 3 to 5 times to ensure repeatability.
For polyamine oligosaccharide affinity studies, a constant voltage of 15 kv was
used at 230 nm detection.
4.2.4 Data Analysis
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The affinities of LMWH and glycosaminoglycan components for linear
polyalkylamines were measured from the change in electrophoretic mobility (µep) as a
function of the concentration of the resolving agent. The µep values were calculated
using equation 1, which is a modified form of that used in the literature [146].

Le
∆µep =

Tmig

(Equation 1)

V
Lt

In this equation, Le is the effective length of the capillary to the detector window,
peak migration time is represented by tmig, and V is the applied constant voltage. This
equation does not include a reference migration term, i.e., the migration time of neutral
marker for reducing run-to-run variations, as reported in the literature [146], because a
neutral marker does not migrate under the strongly acidic conditions, which suppress
electro-osmotic force. To reduce incidental run-to-run variations under reverse polarity
conditions, the average current for each run (66-72 µA range) was used to normalize
migration times and mobilities.
The affinity (KD) of polyalkylamine for GAG components was calculated using
equation 2, which is an adaptation of the Scatchard equation. In this equation, ∆µep is
the change of electrophoretic mobility of a given CE peak in the presence of resolving
agent (RA) as compared to that in its absence (µ0ep.) Because the resolved peaks are
not distinguishable without the RA, the mobility of a peak at the start of the
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electropherogram in the absence of RA (~15 min) was used as µ0ep. KD, the equilibrium
dissociation constant, was calculated from the slope of the plot.

∆µep
[RA]

= -

∆µep
+

KD

∆µep
max

(Equation 2)

KD

4.3 Results
4.3.1 The Interaction of Linear Polyamines With Various Glycosaminoglycans

In chapter 2, linear polyalkylamines were used to fingerprint enoxaparin,
tinzaparin and a generic LMWH [19]. Positively charged polyalkylamines (figure 2.2)
recognize a collection of negatively charged sulfate groups on LMWH chain resulting in
a fingerprint pattern. Because each LMWH is structurally distinct, its CE profile in the
presence of RA was found to be characteristic of its composition (figure 2.9). In a
manner similar to LMWHs, other GAGs are also structurally distinct in terms of
constituent residues, inter-residue linkages, and the overall three dimensional
organization of anionic groups. We reasoned that these features should induce
differential recognition of GAGs by linear polyalkylamines. To test this hypothesis, we
subjected UFH, CS and DS, the three most common available GAGs, to the
fingerprinting protocol developed for LMWHs. This allowed us to discern why RA’s
interact with sulfated polysaccharides based on what is known about the structures of
the GAGs studied.

78

Figure 4.2A shows CE profiles of AMAC-labeled UFH, CS and DS in the

presence and absence of 5EH, a representative RA. All three polymeric GAGs gave
broad peaks in the absence of 5EH. UFH eluted in about 20 mins, while CS and DS
eluted between 26 – 28 mins, which was in accordance with their negative charge
density. In the presence of 200 µM 5EH, a concentration found to readily fingerprint
enoxaparin, the broad CS peak shifted to about 30 min indicating weak interaction with
the RA that is not sufficient to induce fingerprinting. In contrast, UFH was essentially
fully resolved into multiple peaks in the presence of 200 µM 5EH (figure 2A) indicating
dramatically different interaction. Interestingly, even 10 µM 5EH resolved UFH into
multiple peaks suggesting a high affinity interaction between the two molecules (not
shown). DS, on the other hand, was separated into two groups of peaks – a broad peak
resembling CS’s broad profile and a cluster of sharp peaks resembling the UFH profile.
This dual distribution profile could be transformed into single multi-peak profile at higher
RA levels, e.g., 500 µM 5EH suggesting that the distribution into two major components
is simply a function of affinity-governed equilibrium. To test whether CS also exhibits
this phenomenon, higher 5EH levels were screened (up to 1000 µM). Although the
migration time of CS gradually increased, no resolution was observed (not shown)
suggesting that the fundamental structural difference between CS and DS is sensed
extremely well by these linear polyalkylamines.
Changing the resolving agent to 4EP, a polyamine with potentially one less
positive charge at pH 2.3 gave results similar to those obtained with 5EH, though the
concentration of 4EP was four times that of 5EH (figure 4.2B). Thus, at 800 µM 4EP,
UFH and DS resolved into multiple peaks (figure 4.2B). In contrast, CS continued to
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display broad peak profile. Higher concentrations of 4EP were necessary to induce
resolution possibly because of its lower affinity for the polymeric polyanions.
Despite the wide difference in the interaction profile of polymeric GAGs with
linear polyalkylamines, it was difficult to truly fingerprint the UFH and DS. Considerable
variation in peak widths, shapes and number was observed between runs for UFH as
reported in chapter 3 and for DS. We theorize that as the UFH:RA multimers resolve, a
dynamic equilibrium is established, which rapidly changes the electrophoretic mobilities
resulting in changes in peak pattern between runs. DS was less susceptible to variation
than UFH, but this changed at higher concentrations of RA. Yet overall, the observation
that UFH and DS, but not CS, interact and resolve well with linear polyalkylamines
indicates that these small molecules could be used as probes for direct analysis of
GAGs.
4.3.2 Fingerprints of Low Molecular Weight Heparins Arises From a Two-site
Interaction Phenomenon

Previous work with LMWH fingerprinting suggested that 5EH was the best RA
among those tested (chapter 2). The above analysis of full-length GAGs showed that
fingerprinting was not possible for CS, was minimal for DS, and unsuitable for UFH
based on their interactions with the RAs. This implied that linear polyalkylamines
selectively fingerprint LMWHs, i.e., shorter polysaccharide chains with high sulfate
density. Between different linear polyalkylamines, however, a certain polycationic
charge density was necessary as decamethonium (figure 4.1) failed to resolve any
LMWH (as well as other GAGs) at concentrations as high 1000 µM (figure 4.3). To
assess the fundamental basis for this phenomenon, fingerprinting profiles of enoxaparin
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were studied with increasing concentrations of 5EH (figure 4.4). The fingerprints were
highly reproducible with a day-to-day variability of < 5% (data not shown). In the
absence of a mass spectrometric assignment of the peaks observed in the fingerprints,
which is expected to be difficult due to lack of baseline resolution, ascertaining the
change in migration time of individual LMWH chains is nearly impossible. However, the
peak shape pattern remains the same as the concentration of 5EH increases. This was
also found for 4EP (figure 4.5) as well as SPM (figure 4.6), enabling the monitoring of
few peaks with high fidelity over a large range of RA concentration. To assess how the
RAs interact with LMWHs chains, we selected two of these high fidelity, representative
peaks for 5EH and 4EP, and one peak for SPM. It is important to recognize that the
selected peaks do not necessarily represent one specific LMWH chain; in fact, these
most probably represent many different chains, except with reasonably similar structural
features that induce co-migration. Thus, for a mixture containing millions of species, the
selected peaks represent chains with higher proportion of structural identity. Each peak
was studied at 8-13 concentrations and electrophoretic mobilities of the peaks were
calculated based on standard literature reported methods.
Figure 4.4-4.6 shows the Scatchard analysis of the interaction of 5EH, 4EP, and

SPM with select peaks of enoxaparin as just described. The 5EH and SPM profiles
show a biphasic interaction phenomenon for both the selected peaks. Typically, a linear
Scatchard plot suggests single site binding, while a biphasic plot indicates two binding
sites with sufficiently different affinities [147]. The observation of two binding modes for
molecules as simple and small as 5EH and 4EP is interesting as well as challenging.
Based on first principles, these LMWH peaks would be expected to display an average
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single-site

interaction

phenomenon

because

the

peaks

are

not

completely

homogeneous and the equilibrium status within the capillary would be dynamic. The
observation of a biphasic binding mode suggests that 5EH and 4EP recognize selected
chains of LMWHs in a highly specific manner. Similar results were obtained for SPM
and enoxaparin, though with only a single peak and with a larger amount of error
compared to 5EH and 4EP at the high affinity concentration (figure 4.6B). Thus, the
similarity across the three RAs studied suggests that this characteristic is likely to be
generally valid for most LMWH chains.
4.3.3 Fingerprinting Arises from Differential Interactions of Different Low
Molecular Weight Heparin Chains

To gain quantitative information regarding the reason for the observation of
fingerprints, we analyzed the observed biphasic profile as arising from two LMWH – RA
equilibria that are not co-operatively linked. Typically, such biphasic profiles arise when
the affinities are sufficiently distinct and thus can be analyzed using the Scatchard
equation on each arm of the profile. Application of equation 2 to each arm of the 5EH –
enoxaparin biphasic profile gave KD values of 123 µM and 0.024 µM for peak 1, and
53.8 µM and <10 nM for peak 2 under the conditions of CE experiment (table 1.1). This
corresponds to differences of 5125- and 5400-fold between the two affinities for both
peaks 1 and 2, respectively. Thus, 5EH displays exceptionally strong affinity for some
LMWH chains (nM), while interacting with perhaps most chains with much lower affinity
(µM). The high affinity interactions most probably correspond to specific recognition of
LMWH chains through the formation of one or more hydrogen bonds, while the low
affinity interaction probably arises from a generalized non-specific Coulombic ion pairing

82

[148]. We believe that the high affinity interactions are the primary reason that
polyalkylamines are able to generate fingerprints since they cause chains with similar
binding profiles to group together to form peaks from which average affinity values can
be obtained.
The affinity difference remains intact for the other two RAs also. Table 4.1 lists
the affinities measured for the selected peaks using Scatchard analysis. Both 4EP and
SPM demonstrate a weaker interaction profile with LMWH chains as compared to that
with 5EH. The high affinity interaction ranged from 0.74 µM to 5.2 µM, which is
approximately 74 – 520-fold weaker than the high affinity interaction observed for 5EH.
In contrast, the low affinity interactions for 4EP and SPM were 267, 308 and 414 µM,
which implies a much weaker 4.9 – 7.7-fold effect. Thus, while the high affinity
interactions are significantly different between the RAs, the low affinity interactions are
fairly similar. These differences in the interactions, especially those of the high affinity
type, generate differences in the fingerprinting profiles with each RA.
An important derivation of these observations is that it should be possible to
develop powerful RAs for specific fingerprinting of these highly complex GAGs. For
example, the affinity of LMWH chains increase with the number of positively charged
amines on the RA. While the strength of the low affinity interaction does not decrease
precipitously, the high affinity interaction is dramatically weakened through a change
from 5EH and 4EP (table 4.1). Hence, it can be expected that longer polyalkylamines,
perhaps linear and/or branched, would resolve LMWHs or GAGs better. It may even
become possible to induce baseline resolution for direct structural analysis using
tandem ESI-MS.
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4.3.4 Tetra, Hexa, and Decasacharide Fingerprints do not Show Two Site Binding
Profiles

Theoretically, oligosaccharides of the same number of sugars would be more
homogeneous and thus easier to analyze than LMWH, UFH, or other GAGs as
structural diversity would be dramatically lower. To shed further light on the interaction
of polycations with GAGs, the interaction purchased heparin oligosaccharides with the
RA’s was also studied. For hexa and decasaccharide, the electropherograms displayed
remarkable homogeneity. Upon the addition of 5EH however, both profiles split into
multiple peaks. This was especially prominent with decasaccharide (figure 4.7).
Tetrasaccharide yielded similar results with 5EH and several other resolving agents (not
shown). Such results were expected since oligosaccharides, while simpler than LMWH,
are still not homogeneous with variation of uronic acid conformation and sulfation
pattern that only increases with length. Affinity studies were unsuccessful to excessive
peak blending at lower concentrations and difficulty in tracking specific peaks across
higher concentrations. It was nearly impossible to identify peaks with certainty.
4.4 Discussion

Structural characterization of GAG chains is challenging because of their
massive structural complexity. This work presents a rather simple protocol of resolving a
group of GAGs through the use of linear polyalkylamines under strongly acidic
electrophoretic conditions. The interaction of these agents with full-length heparin was
found to be unusually strong. In fact, the affinity of UFH for linear polyalkylamines is
likely to be lower than that of LMWH, which was found to be in the range of 10 nM.
Structurally, UFH is a linear helical molecule [149] that presents its sulfate groups on
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the surface resulting in greater number of polycationic recognition motifs than possible
for LMWHs. Further, a three-fold longer heparin chain affords a major statistical
advantage resulting in higher affinity for the RAs.
Unfortunately, UFH’s significantly higher affinity did not translate into a
fingerprinting advantage. Although UFH could be resolved into multiple peaks, the CE
profile is not reproducible as noted for LMWHs [19]. The likely reason for this
phenomenon is the possibility of high-affinity induced dynamic equilibrium between
multiple equivalent binding sites on UFH chains for linear polyalkylamines and the
formation bridges between GAG chains as discussed in chapter 3. While the dynamic
equilibrium during electrophoresis is also present for LMWHs, the reduced affinity of
RAs engineers an averaging effect resulting in high reproducibility. An alternative, less
likely, explanation is that LMWHs and UFH are structurally distinct. The fact that
LMWHs are derived from UFH from either chemical, enzymatic, or chromatographic
means implies that the microstructures of the two species are likely to be similar. Yet,
the dramatically distinct response of LMWHs and UFH to linear polyalkylamines is
interesting and worth investigating. If either of the two hypotheses regarding UFH –
linear polyalkylamine interaction is true, longer chains of RAs, e.g., a polyamine three
times longer than 5EH, can be expected to fingerprint UFH at appropriately lower
concentrations. Such polyamines are known in the literature [150-151] and may offer
fingerprinting advantage, but may also carry cytotoxic and/or carcinogenic adverse
effects [152-153].
Fingerprinting of LMWHs is highly dependent on the structure of the RA as
demonstrated here as well in chapter 2. Affinity measurements performed here
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demonstrate that optimal chain length and positive charge density are crucial for
achieving resolution. Comparison of structures shows that UFH/LMWH, DS, and CS
contain an average of 2.4, 1.2, and 0.95 sulfate groups per disaccharide, respectively,
in their representative sequences [143]. This suggests that linear polyalkylamines
studied here are effective when sulfate charge density is more than one per
disaccharide (most carboxylates are expected to be protonated at pH 2.3). Yet, the
ability of these RAs to interact with GAGs is not just dependent on sulfate charge
density. OSCS, which is expected to possess sulfate density much greater than 1.2,
does not interact strongly with linear polyalkylamines. This suggests an intricate
structural component to these interactions.
Finally, the fundamental insight into the basis for fingerprinting of LMWHs by
linear polyalkylamine-based resolving agents will be of value to the design of advanced
resolving agents. Compounds with varying charge density, electrophoretic mobility, and
conformation flexibility could be designed and screened. The possibility of baseline
resolution in these profiles will facilitate direct mass spectrometric analysis for deduction
of heparin sequences as well as for chemoinformatic profiling.
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Table 4.1: Affinities of Selected Enoxaparin Chains for Resolving Agents.

5EH

4EP
SPM

Peak #a

High Affinity
Interaction
(µM)b

Low Affinity
Interaction
(µM)b

Ratio of High to Low
Affinity

1
2

0.024
<0.01

123
54

5125
>5400

1

1.9

312

165

2

0.74

263

355

1

5.2

417

80

a

Peaks are identified in Figure 4. bThe affinities of peaks were measured through
Scatchard analysis. See Materials and Methods section.
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Figure 4.1: The structure of decamethonium.
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Figure 4.2: Interaction of linear polyalkylamines with glycosaminoglycans.
Resolution of CS, DS, and UFH with 200 µM 5EH (A) and 800 µM 4EP (B). CE was
performed in reverse polarity mode in 50 mM sodium phosphate buffer, pH 2.3,
containing 10% DMSO at 10 kV and 15°C. A 75 µM (i.d.) capillary, which as 50 cm to
the detector window, was used for these experiments. The profiles have been offset to
enhance clarity.
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Figure 4.3: Fingerprints Enoxaparin, UFH, CS, and DS (A-D) with
decamethonium. Upper diagram (A): without resolving agents. Lower
diagram (B): with 500 µM decamethonium. decamethonium.
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Figure 4.4: Affinity Data for 5EH and Enoxaparin. A) Resolution of LMWH with
increasing concentrations of 5EH. CE was performed in 50 mM sodium phosphate
buffer, pH 2.3 containing 10% DMSO and fixed concentration of the RA at 10 kV and
15°C. Only selected profiles, offset to enhance clarity, are shown. Typically 3 – 4
experiments were performed at each concentration to ensure high reproducibility. The
observed fingerprint patterns are highly consistent for LMWHs. Individual peaks, e.g., 1
and 2, can be followed as a function of RA concentration. See text for details. B)
Scatchard analysis of mobility data acquired from peak 1 (square) and peak (2).
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Figure 4.5: Affinity Data for 4EP and Enoxaparin. A) Resolution of LMWH with
increasing concentrations of 4EP. Conditions were the same as in figure 4. The
observed fingerprint patterns are highly consistent for LMWHs. Individual peaks, e.g., 1
and 2, can be followed as a function of RA concentration. See text for details.
B) Scatchard analysis of mobility data acquired from peak 1 (square) and peak 2
(circle).
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Figure 4.6: Affinity Data for SPM and Enoxaparin. A) Resolution of LMWH with
increasing concentrations of SPM. Conditions were the same as in figure 4.
B) Scatchard analysis of mobility data acquired from the indicated peak.
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Figure 4.7: Fingerprints of decasaccharide and hexasaccharide using 5EH. The
concentrations used are A) 0 µM, B) 40 µM, C) 100 µM, D) 250 µM.
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A Batch to Batch Capillary Electrophoretic Analysis of Low Molecular
Weight Heparins

5.1 Background

The issue of biosimilar LMWHs issue has come to prominence in recent years
with the branded products approaching the end of their patent life and generics entering
clinic around the world. Yet the sheer complexity of these products means that
developing an equivalent product would prove very difficult. Differences between brand
and generic LMWHs have been noted especially with regards to LovenoxTM and generic
enoxaparin products available in other countries [139]. The fundamental question is this:
can a true generic formulation of LMWH be structurally identified with reasonable
degree of certainty? Alternatively, can a prospective LMWH be reliably differentiated at
an early stage from that used in the clinic?
In July of 2010, the FDA approved the first LMWH for use in the US as a generic
equivalent of enoxaparin. While substantial in vivo and in vitro tests were performed to
establish equivalence, structural equivalence was limited to molecular weight
distribution and 1,6-anhydromannose ring proportion [31,32]. Considering the
complexity of LMWHs, establishing biosimilarity with just two structural techniques is a
dangerous proposition. Yet, structural analysis of intact LMWHs is a challenging
endeavor. A wide range of electrophoretic, chromatographic, spectroscopic and mass
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spectrometric

techniques

have

been

used

for

heparin

disaccharide

and

oligosaccharides [76-78,101,155], but few protocols exist for intact LMWHs [101, 155158].
Patel et al. developed a reverse phase HPLC method using tetrabutylammonium
hydroxide as an ion pairing agent that produced highly resolved chromatograms of
intact enoxaparin and dalteparin that displayed notably different profiles [100]. Excellent
resolution of a mixture of oligosaccharides with degree of polymerization ranging from 6
to 22 was achieved using reverse phase-ion pairing UPLC coupled to mass
spectrometry, which was extended to generate a tinzaparin chromatogram of over 50
peaks [101]. Outside of these methods, advanced multi-dimensional NMR spectroscopy
and advanced electrospray ionization-MS methods have been developed [41,85,123],
but their wide-spread applicability is doubtful.
Having

developed

a

protocol

for

characterizing

LMWHs

with

linear

alkylpolyamines and capillary electrophoresis, we sought to assess whether generic
enoxaparin is structurally equivalent to Lovenox as analyzed by our high-resolution CE
fingerprinting protocol. Fingerprinting using multiple resolving agents shows that both
generic and brand name enoxaparin behave in an essentially identical manner across a
range of conditions suggesting essentially identical structural composition. More
specifically, our protocol reveals that two batches of brand name enoxaparin studied are
sufficiently different to accommodate generic enoxaparin within their realm. In contrast,
enoxaparin and tinzaparin display widely different fingerprints suggesting that our
fingerprinting protocol is extremely robust to rapidly assess compositional, and hence
structural, equivalence. This work contributes to assessing the chemical equivalence of
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LMWH formulations and lays the groundwork for evaluating future generics and brands
expected to enter the clinic.

5.2 Materials and Methods
5.2.1 Chemicals

LovenoxTM (Lot #15146 and #29411), generic enoxaparin (Sandoz, Lot #914690),
and InnohepTM (Lot #DC1863 and #DC9158) were purchased from Virginia
Commonwealth University Health Systems Pharmacy. 2-Aminoacridone (AMAC),
DMSO, and dibasic sodium phosphate were purchased from Sigma-Aldrich (St. Louis,
MO). Pentaethylenehexamine (5EH), tetraethylenepentamine (4EP), and spermine
(SPM) were purchased from Acros Organics (Geel, Belgium). Fused silica capillary was
purchased from Microsolv Corporation (Eatontown, NJ). Sodium cyanoborohydride was
purchased from Fisher Scientific (Pittsburgh, PA). G-10 media was purchased from GE
Healthcare (Little Chalfont, UK). Cellulose ester dialysis membranes (500-1000
molecular weight cutoff) were purchased from Spectrum Laboratories (Rancho
Dominguez, CA). All other chemicals and reagents were either from Sigma-Aldrich or
Fisher.
5.2.2 Labeling of LMWHs with Aminoacridone

Enoxaparin and tinzaparin were labeled in a manner similar to that reported
earlier. Briefly, 10 mg AMAC was dissolved in 860 µL of an 85% solution of
DMSO/acetic acid and mixed with 860 µL aqueous solution containing 40-80 mg
LMWH. The mixture was allowed to incubate for ~12 h at 37°C followed by addition of
200 mg of sodium cyanoborohydride in water. The reaction was allowed to proceed for
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6 more hours at 37°C. The unreacted aminoacridone was removed via a G-10 column
and the AMAC-labeled LMWH was dialyzed against 2 liters of water for 24 hours using
membrane with a molecular weight cutoff of 500-1000. Following three changes of
water, the solution lyophilized to yield pure AMAC-labeled LMWH. Each preparation of
AMAC-labeled LMWH was redissolved in water to yield a stock solution of 50 mg/ml
and stored at -80°C until use.
5.2.3 Capillary Electrophoresis

CE

was

performed

using

a

Beckman-Coulter

P/ACE

MDQ

capillary

electrophoretic system with a fused silica capillary (I.D. 75 µM) of 50 cm length and 40
cm to the detector window. At the beginning of each day, the capillary was conditioned
with 0.5 M sodium hydroxide, water, 0.5 M phosphoric acid, and finally water. The
capillary was rinsed with run buffer (50 mM dibasic sodium phosphate, pH 2.3) for 2
minutes before each run and periodically with hydroxide, acid, and water. After rinsing,
LMWH samples were diluted to either 4 (enoxaparin) or 1 mg/ml (tinzaparin) and
injected into the capillary for 8 s at 1 PSI. Runs were performed at a constant current of
90 µA at a temperature of 15°C. Each run was completed four times to ensure
reproducibility. For figure 5.8, all LMWH concentrations were 1 mg/ml.
5.2.4 NMR Analysis of Low Molecular Weight Heparins
1

H-NMR and

13

C-NMR spectroscopy was performed on a 400 MHz Bruker

Ultrasheild plus NMR spectrometer. Unlabeled LMWH (40-50 mg) was dissolved in D2O
and lyophilized twice to remove H2O. The sample was then re-dissolved in D2O and 1HNMR spectrum acquired.

13

C-NMR spectra were taken overnight using 10,000 scans

with a line broadening factor of 10 to maximize the signal to noise ratio.
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5.3 Results
5.3.1 Qualitative Analysis of LMWH Fingerprints and NMR Spectra

Following the protocol developed earlier, fingerprints of two lots of Lovenox and
one lot of generic enoxaparin (from Sandoz) were developed using 250, 500 and 1000
µM of three linear polyalkylamines, 5EH, 4EP and SPM, respectively. No differences
were noted without resolving agents. Qualitatively, the fingerprints reveal striking
similarities between the brand and generic enoxaparins as seen in figures 5.1-5.3,
where the fingerprints have been aligned on the X-axis by designated peaks and
expanded along the Y-axis to compensate for the lack of an internal standard and to
enable minor peaks to be seen more easily. SPM and 4EP show the most similarities,
while 5EH shows some variation (see close ups, figures 5.1-5.3). Figures 5.4-5.6 show
unadjusted electropherograms of the same runs. The three batches of enoxaparin
displayed several major peaks in the presence of 4EP and SPM, which migrated in an
essentially identical manner (within ~1.5 min). The migration times varied consistently
more with 5EH, especially for later peaks (~2.5 – 4 min) of lot #29411, probably due to
the higher affinity of this resolving agent. Alternatively, lot #29411 may possess a
slightly altered overall sulfation pattern, which measurably affects electrophoretic
mobility. Such variation is important and can be addressed with larger sample size,
however, this was beyond the scope of our project.
Two batches of tinzaparin were also analyzed (generic tinzaparin is not available,
as yet) with 1000 µM SPM and 200 µM 4EP (figure 5.7). The tinzaparin fingerprints
were highly consistent across the batches with major peaks migrating at nearly identical
times and no obvious difference in resolution. It is notable that at 200 µM 4EP (figure
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5.7B), tinzaparin features “noise” peaks similar to that seen with UFH at ~45 minutes

and beyond. Given that tinzaparin is acquired via enzymatic digestion of UFH, it is likely
that it retains more of UFH’s basic structural features than chemically depolymerized
LMWH and will thus behave in a similar manner. Interestingly, the “noise” peaks
become more prominent and begin interfering with the main peak body when
concentration of tinzaparin sample is raised. In spite of their similarities to each other,
tinzaparin fingerprints are widely different from enoxaparin fingerprints. Figure 5.8
shows a comparison of two tinzaparin and three enoxaparin batches in the presence of
200 µM 4EP. Major differences in group of peaks at ~22 and ~27 min are obvious.
Interestingly, the ‘center of gravity’ of the tinzaparin profile is significantly delayed as
compared to enoxaparin, which may indicate an average lower charge to mass ratio.
To assess whether such similarities and differences are picked up by 1H and

13

C

NMR spectroscopy, we recorded the spectra for all LMWH batches. While expected
peaks such as those representing the N-acetyl protons at ~ 2-2.05 ppm were seen,
none of the spectra demonstrated any difference for the enoxaparin or the tinzaparin
batches (figure 5.9-12). Between enoxaparin and tinzaparin, both 1H and

13

C NMR

spectra were noted to be different, but the differences were not as obvious as revealed
by fingerprinting protocol. This indicates that the structural heterogeneity of these
LMWH preparations is so high that the resulting peak broadening in NMR spectra
accommodates minor structural differences.
5.3.2 Quantitative Analysis of LMWH Fingerprints

To more accurately compare the LMWH fingerprints, detailed analysis was
performed for each profile. Notable differences emerged for several peaks in terms of
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both area and height. For example, peak 2 for enoxaparin resolved with 5EH (figure
5.4) displayed different areas of (2.9±0.2)×106, (3.1±0.2)×106, and (1.7±0.05)×106 for

one generic and two batches of Lovenox. Similar differences were also calculated for
enoxaparins with 4EP and SPM (figure 5.5-5.6). However, considering the absence of
a fixed reference in these fingerprints, such differences could possibly be explained by
non-structural or compositional reasons. Thus, relative changes in the proportions of the
resolved components were evaluated using peak 1 as a reference point as this would
allow the comparison of enoxaparin lots while correcting for differences in percent
labeling. Table 5.1 shows the ratio of area for peaks 2 as a proportion of peak 1 for
enoxaparin fingerprints in the presence of 250 µM 5EH, resulting in values of 4.7, 6.98
and 2.98 for generic batch 914690 and LovenoxTM 15146 and 29411 respectively. The
differences between these are substantial and reaches over 100% when comparing the
brand batches to one another, differences in each ratio can be noted between the two
batches of Lovenox. In fact, the ratios of various peaks displayed substantial variation
across the two batches of Lovenox. Generic enoxaparin displayed ratios different from
either Lovenox lots, but within the range defined by the two batches of the brand
enoxaparin (see figure 5.4 and table 5.1). These conclusions remained the same when
peak area ratios were evaluated with 4EP or SPM fingerprints (see figure 5.5-5.6 and
table 5.2-5.3).
5.4 Discussion

Our earlier work on the mechanistic basis of LMWH fingerprinting indicated that
each linear polyalkylamine studied, i.e., 5EH, 4EP and SPM, interacted with the
polyanionic polysaccharide with high affinity (chapters 2 and 4). More importantly, a
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biphasic interaction phenomenon was observed, thus explaining the highly specific
fingerprint achieved with each polyalkylamine. This led to the idea that as a group these
polybasic molecules might help identify small differences between different LMWHs and
especially pinpoint differences between different batches of the same LMWH, if any.
This idea is exciting because high resolution fingerprints coupled with nano-MS
technology may provide a robust, operational platform for quick assessment of
‘biosimilarity’ [101].
To our knowledge, rigorous comparison of brand and generic enoxaparin has not
been reported in the literature, although it has been widely recognized that generic
LMWH may be technologically difficult to achieve [139,154,159]. Our effort is the first
bioanalytical comparison of Lovenox with its generic version. Using the three molecule
toolbox, our analysis suggests that the two enoxaparins are remarkably similar within
limits of experimental error. In fact, the two batches of Lovenox display greater variance
between them for all three polyalkyamine resolving agents, which accommodates the
generic enoxaparin reasonably well. This result is striking and appears to indicate that
the variation in the manufacture of the brand LMWH may be sufficiently high to
accommodate several versions of generic.
Given that the fingerprints are the results of structure-specific interactions of the
resolving agents with LMWH chains, the variations in the fingerprints imply detectable
differences in the chemical composition of Lovenox from batch to batch. This difference
is less with regard to the type of polysaccharide species and more with regard to the
proportion of species. This work provides a stimulus for a wider study with much higher
sample size so as to define the limits better. Yet, whether these structural differences
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necessarily imply functional (beneficial and adverse) differences remains unevaluated,
although theoretically a direct correlation is predicted.
Our study demonstrated a higher level of consistency between the two batches
of tinzaparin studied here. More importantly, the resolution with polyalkylamines was so
high that massive differences were evident between tinzaparin and enoxaparin. This
was in striking contrast to one-dimensional 1H and

13

C NMR spectra that failed to

display much differences. The work, therefore, highlights the limitations of onedimensional NMR spectroscopy in such analysis, while showcasing the power of linear
polyalkylamine-based CE fingerprinting.
Finally, although limited in scope our effort provides a glimpse into the inter-batch
variability and puts forward a robust platform for assessing structural biosimilarity of
LMWHs. The use CE-MS could greatly expand this protocol. The bioanalytical
fingerprinting is no substitute for clinical and epidemiological data, but could form an
inexpensive method for rapid evaluation of ‘biosimilarity’. Considering that more generic
LMWHs are being prepared for clinical entry, our protocol would be handy.
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Figure 5.1: Comparison of enoxaparin fingerprints in the presence of 250 µM
5EH. Lot numbers from the bottom: 914690, 15146, 29411. Electropherograms have
been aligned by peaks aligned with the peak marked by (*) for ease of comparison. Yvalues have been multiplied for optimum to increase peak height.
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Figure 5.2: Comparison of enoxaparin fingerprints in the presence of 500 µM
4EP. Lot numbers from the bottom: 914690, 15146, 29411. Electropherograms have
been aligned by peaks aligned with the peak marked by (*) for ease of comparison. Yvalues have been multiplied for optimum to increase peak height.
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Figure 5.3: Comparison of enoxaparin fingerprints in the presence of 1000 µM
SPM. Lot numbers from the bottom: 914690, 15146, 29411. Electropherograms have
been aligned by peaks aligned with the peak marked by (*) for ease of comparison. Yvalues have been multiplied for optimum to increase peak height.
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Figure 5.4: Unmodified enoxaparin batch fingerprints acquired with 250 µM 5EH.
Analysis of the highlighted and numbered peaks are seen in table 5.1.

Table 5.1: Peak area analysis of enoxaparin batches with 250 µM 5EH.

Area
Peak
Ratio

Area

Enoxaparin 914690
Pk 1
Pk 2
Pk 3
Pk 2:1
Pk 3:1
Pk 3:2

Mean
63377
297710
274201
4.70
4.33
0.92

Stdev
7267
22649
25475
0.90
0.90
0.16

Lovenox 15146
Mean
44530
310995
250014
6.98
5.61
0.80
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Stdev
2792
16863
19755
0.82
0.80
0.11

Lovenox 29411
Mean
59336
176577
144012
2.98
2.43
0.82

Stdev
7739
5099
5355
0.47
0.41
0.05

Absorbance at 254 nm

0.035
0.03
0.025
0.02
0.015
0.01
0.005
0

2

3

4

2

3

4

29411

1

1

15146
2

3

4

1

15

914690

25

35

45

55

Time (minutes)
Figure 5.5: Unmodified enoxaparin batch fingerprints acquired with 500 µM 4EP.
Analysis of the highlighted and numbered peaks are seen in table 5.2.

Table 5.2: Peak area analysis of enoxaparin batches with 500 µM 4EP.

Area
Peak Ratio

Peak Area

Enoxaparin 914690
Pk 1
Pk 2
Pk 3
Pk 4
Pk 2:1
Pk 3:1
Pk 3:2
Pk 4:1
Pk 4:2

Mean
68187
272719
236724
356554
4.00
3.47
0.87
5.23
1.31

Stdev
11706
20369
20613
24984
0.985
0.898
0.140
1.264
0.420

Lovenox 15146
Mean
36841
251961
235613
275923
6.84
6.40
0.94
7.49
1.10
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Stdev
4653
11216
11080
10681
1.168
1.108
0.086
1.236
0.236

Lovenox 29411
Mean
44525
135537
124493
215826
3.04
2.80
0.92
4.85
1.59

Stdev
1857
13891
16653
19855
0.439
0.491
0.217
0.648
0.393
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Figure 5.6: Unmodified enoxaparin batch fingerprints acquired with 1000 µM
SPM. Analysis of the highlighted and numbered peaks are seen in table 5.3.

Table 5.3: Peak area analysis of enoxaparin batches with 1,000 µM SPM.

Area
Peak Ratio

Peak Area

Enoxaparin 914690
Pk 1
Pk 2
Pk 3
Pk 4
Pk 5
Pk 2:1
Pk 3:1
Pk 4:1
Pk 5:1
Pk 5:2
Pk 3:2
Pk 4:3
Pk 5:3

Mean
79393
41337
242483
109210
457733
0.52
3.05
1.38
5.77
11.07
5.87
0.45
1.89

Stdev
2768
1299
8371
5231
19401
0.03
0.21
0.11
0.45
0.82
0.39
0.04
0.15

Lovenox 15146
Mean
62632
41846
216374
94834
461615
0.67
3.45
1.51
7.37
11.03
5.17
0.44
2.13
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Stdev
4400
1389
10043
13114
23927
0.07
0.40
0.32
0.90
0.94
0.41
0.08
0.21

Lovenox 29411
Mean
61453
33194
141178
115188
296239
0.54
2.30
1.87
4.82
8.92
4.25
0.82
2.10

Stdev
7766
7514
6794
5279
16357
0.19
0.40
0.32
0.88
2.51
1.17
0.08
0.22
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Figure 5.7: Batch to batch tinzaparin comparison. A) 1000 µM SPM, B) 200 µM
4EP. No adjustments made to data.
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Figure 5:8: Tinzaparin and enoxaparin batches in the presence of 200 µM 4EP. All
GAG concentrations 1 mg/ml. Batches beginning with DC are tinzaparin. The data
points have been multiplied on the Y axis to increase peak height and allow for easy
comparisons. No adjustment made on the X-axis.
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Figure 5:9: 1H-NMR of enoxaparin batches in D2O.
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29411

15146

914690

Figure 5:10: 13C-NMR of enoxaparin batches in D2O. A line broadening factor of 10
was used to maximize the signal to noise ratio.
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DC9158

DC9158

Figure 5:11: 1H-NMR of tinzaparin batches in D2O.
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DC9158

DC1863

Figure 5.12: 13C-NMR of tinzaparin batches in D2O. A line broadening factor of 10
was used to maximize the signal to noise ratio.
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